US20190175506A1 - Loading of Extracellular Vesicles through Imparting of Mechanical Shear - Google Patents
Loading of Extracellular Vesicles through Imparting of Mechanical Shear Download PDFInfo
- Publication number
- US20190175506A1 US20190175506A1 US16/190,058 US201816190058A US2019175506A1 US 20190175506 A1 US20190175506 A1 US 20190175506A1 US 201816190058 A US201816190058 A US 201816190058A US 2019175506 A1 US2019175506 A1 US 2019175506A1
- Authority
- US
- United States
- Prior art keywords
- vesicle
- payload
- canceled
- extracellular vesicles
- homogenization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000011068 loading method Methods 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 59
- 238000000265 homogenisation Methods 0.000 claims abstract description 48
- 210000004027 cell Anatomy 0.000 claims description 112
- 108020004459 Small interfering RNA Proteins 0.000 claims description 68
- 210000001808 exosome Anatomy 0.000 claims description 33
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 32
- 108020004999 messenger RNA Proteins 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 235000012000 cholesterol Nutrition 0.000 claims description 17
- 108091070501 miRNA Proteins 0.000 claims description 17
- 239000002679 microRNA Substances 0.000 claims description 17
- 150000002632 lipids Chemical class 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 9
- 239000003053 toxin Substances 0.000 claims description 9
- 231100000765 toxin Toxicity 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 210000001163 endosome Anatomy 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- 229940126586 small molecule drug Drugs 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 5
- 230000001640 apoptogenic effect Effects 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 108020005544 Antisense RNA Proteins 0.000 claims description 3
- 229940044665 STING agonist Drugs 0.000 claims description 3
- 239000008366 buffered solution Substances 0.000 claims description 3
- 239000003184 complementary RNA Substances 0.000 claims description 3
- 210000003712 lysosome Anatomy 0.000 claims description 3
- 230000001868 lysosomic effect Effects 0.000 claims description 3
- 239000000693 micelle Substances 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000004055 small Interfering RNA Substances 0.000 description 58
- 102000039446 nucleic acids Human genes 0.000 description 39
- 108020004707 nucleic acids Proteins 0.000 description 39
- 150000007523 nucleic acids Chemical class 0.000 description 39
- 108090000765 processed proteins & peptides Proteins 0.000 description 33
- 239000003814 drug Substances 0.000 description 32
- 239000000203 mixture Substances 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 29
- 229920001184 polypeptide Polymers 0.000 description 28
- 239000012528 membrane Substances 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 229940124597 therapeutic agent Drugs 0.000 description 19
- 238000003197 gene knockdown Methods 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 101150105104 Kras gene Proteins 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 150000003384 small molecules Chemical class 0.000 description 10
- 210000000170 cell membrane Anatomy 0.000 description 9
- 229920002521 macromolecule Polymers 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- -1 zwitterions Chemical class 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 150000002605 large molecules Chemical class 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102200006539 rs121913529 Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000001542 size-exclusion chromatography Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 108020005198 Long Noncoding RNA Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 230000034303 cell budding Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000010924 continuous production Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000034217 membrane fusion Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000728117 Homo sapiens Plasma membrane calcium-transporting ATPase 4 Proteins 0.000 description 2
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100029743 Plasma membrane calcium-transporting ATPase 4 Human genes 0.000 description 2
- 102100035533 Stimulator of interferon genes protein Human genes 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002575 chemical warfare agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000003667 hormone antagonist Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000004886 process control Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 235000021309 simple sugar Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940123611 Genome editing Drugs 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000052923 Heavy Chain Fusion Regulatory Protein 1 Human genes 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000728095 Homo sapiens Plasma membrane calcium-transporting ATPase 1 Proteins 0.000 description 1
- 101000728125 Homo sapiens Plasma membrane calcium-transporting ATPase 2 Proteins 0.000 description 1
- 101000728115 Homo sapiens Plasma membrane calcium-transporting ATPase 3 Proteins 0.000 description 1
- 101000931590 Homo sapiens Prostaglandin F2 receptor negative regulator Proteins 0.000 description 1
- 101000701334 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-1 Proteins 0.000 description 1
- 101000753197 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-2 Proteins 0.000 description 1
- 101000753178 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-3 Proteins 0.000 description 1
- 101000753174 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-4 Proteins 0.000 description 1
- 101000974834 Homo sapiens Sodium/potassium-transporting ATPase subunit beta-3 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 101150091468 IGSF8 gene Proteins 0.000 description 1
- 101150018316 Igsf3 gene Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100022519 Immunoglobulin superfamily member 3 Human genes 0.000 description 1
- 102100036489 Immunoglobulin superfamily member 8 Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102100029751 Plasma membrane calcium-transporting ATPase 1 Human genes 0.000 description 1
- 102100029744 Plasma membrane calcium-transporting ATPase 3 Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102100020864 Prostaglandin F2 receptor negative regulator Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108091006313 SLC3A2 Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102100030458 Sodium/potassium-transporting ATPase subunit alpha-1 Human genes 0.000 description 1
- 102100021955 Sodium/potassium-transporting ATPase subunit alpha-2 Human genes 0.000 description 1
- 102100021952 Sodium/potassium-transporting ATPase subunit alpha-3 Human genes 0.000 description 1
- 102100021951 Sodium/potassium-transporting ATPase subunit alpha-4 Human genes 0.000 description 1
- 102100022792 Sodium/potassium-transporting ATPase subunit beta-3 Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000013072 incoming material Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108091005706 peripheral membrane proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000472 rate-zonal centrifugation Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102220311754 rs191837710 Human genes 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Definitions
- the therapeutic properties of extracellular vesicles can be enhanced by the complexation of a molecule or molecules in a process referred to as loading.
- Loading represents the encapsulation, partial engulfment, and/or external association of a cargo molecule with the vesicle or vesicles.
- Methods that facilitate the loading of molecules into or onto vesicles can improve efficiency and enable the loading of diverse classes of molecules. Homogenization, the application of shear and cavitation, can be applied simultaneously to both vesicles and the desired payload to promote loading of the payload into and/or on to the vesicle.
- Homogenization including microfluidization (a branded from of homogenization) has been previously employed for nanoencapsulation and loading of liposomes but has not been used for the loading of vesicles.
- Disclosed herein are methods for producing an isolated extracellular vesicle for delivery of a payload molecule comprising modifying an extracellular vesicle with a payload molecule via homogenization, isolating the modified extracellular vesicle containing the payload molecule, and optionally formulating the isolated modified extracellular vesicle into a pharmaceutical composition.
- the vesicle is an exosome, a nanovesicle, an apoptotic body, a microvesicle, a lysosome, an endosome, an enveloped virus, a viral vector, a liposome, a lipid nanoparticle, a micelle, a multilamellar structure, a revesiculated vesicle, or an extruded cell.
- the payload molecule is a therapeutic molecule.
- the vesicle is modified with a plurality of payload molecules.
- the homogenization is microfluidization.
- the microfluidization is a single pass. In other embodiments, the microfluidization is multiple passes.
- the pressure of the microfluidization is performed between 10,000 to 30,000 pounds per square inch (psi). In one embodiment, the microfluidization is 10,000 psi. In one embodiment, the microfluidization is 20,000 psi. In one embodiment, the microfluidization is 30,000 psi. In some embodiments, the pressure is the same in multiple passes. In other embodiments, the pressure is different in multiple passes.
- the vesicle is in buffered solution.
- the solution is between a pH 3 and 13.
- the pH of the solution is between 7 and 8.
- the pH of the solution is 7.4.
- the buffered solution comprises phosphate buffered saline and 0.5-5% sucrose.
- the volume of the microfluidization is less than a liter. In other embodiments, the volume of the microfluidization is more than a liter. In another embodiment, the volume of the microfluidization is at least 1 ml.
- the microfluidization is performed at 15° C. to 80° C. In another embodiment, the microfluidization is performed at room temperature. In some embodiments, the microfluidization is performed at 70-80° C.
- the payload is siRNA, miRNA, antisense RNA, DNA, a plasmid, mRNA, tRNA, a protein, a carbohydrate, a lipid, a small molecule drug, a toxin, an antibody, a recombinant protein, a viral vector, or a vaccine.
- the payload is siRNA.
- the payload is a modified nucleic acid.
- said modified nucleic acid is an siRNA or miRNA that is modified to additionally comprise one or more cholesterol molecules.
- said cholesterol is chemically conjugated to the 5′ end of the sense, or passenger strand of the siRNA or miRNA.
- said cholesterol is chemically conjugated to the 3′ end of the sense, or passenger strand of the siRNA or miRNA. In some embodiments, said cholesterol is chemically conjugated to the 5′ end of the antisense, or guide strand of the siRNA or miRNA. In some embodiments, said cholesterol is chemically conjugated to the 3′ end of the antisense, or guide strand of the siRNA or miRNA.
- a solution comprising the vesicle and the payload are first mixed and the mixture is homogenized. In some embodiments, a solution comprising the vesicle is homogenized first and the payload is added to the homogenized vesicle solution.
- the vesicle is modified with a plurality of payload molecules.
- the payload molecules are predominantly on the surface of the modified vesicle. In another embodiment, the payload molecules are predominantly inside the modified vesicle.
- the vesicle in solution is both homogenized and treated with another technology for loading the payload molecules.
- the additional treatment is a chemical treatment.
- vesicle is post-treated after homogenization. In another embodiment, the vesicle is pre-treated before homogenization.
- the vesicles may be homogenized in a batch, a semi-batch, or a continuous process.
- FIG. 1 shows the qPCR results from kras gene knockdown cell based assay in Panc-1 cells as a function of shear pressure.
- the left bar shows samples homogenized at 10,000 psi
- the middle bar shows the samples homogenized at 20,000 psi
- the right bar shows the samples homogenized at 30,000 psi.
- FIG. 2 shows the qPCR results from kras gene knockdown cell based assay in Panc-1 cells as a function of siRNA concentration.
- FIG. 3 shows the qPCR results from kras gene knockdown cell based assay in Panc-1 cells using unmodified siRNA and cholesterol-tagged siRNA loaded in exosomes by microfluidic homogenization.
- FIGS. 4A-B show the anion exchange chromatogram profile of unmodified siRNA ( 4 A) and cholesterol-tagged siRNA ( 4 B) after repeated rounds of microfluidic homogenization.
- FIGS. 5A-B show the results from measuring the diameter of purified exosomes after repeated rounds of microfluidic homogenization as determined by size exclusion chromatography ( 5 A) and nanoparticle tracking assay ( 5 B).
- extracellular vesicle refers to a cell-derived vesicle comprising a membrane that encloses an internal space.
- Extracellular vesicles comprise all membrane-bound vesicles that have a smaller diameter than the cell from which they are derived.
- extracellular vesicles range in diameter from 20 nm to 1000 nm, and may comprise various macromolecular cargo either within the internal space, displayed on the external surface of the extracellular vesicle, and/or spanning the membrane.
- Said cargo may comprise nucleic acids, proteins, carbohydrates, lipids, small molecules, and/or combinations thereof.
- extracellular vesicles include apoptotic bodies, fragments of cells, vesicles derived from cells by direct or indirect manipulation (e.g., by serial extrusion or treatment with alkaline solutions), vesiculated organelles, and vesicles produced by living cells (e.g., by direct plasma membrane budding or fusion of the late endosome with the plasma membrane).
- Extracellular vesicles may be derived from a living or dead organism, explanted tissues or organs, and/or cultured cells.
- the term “nanovesicle” refers to a cell-derived small (between 20-250 nm in diameter, more preferably 30-150 nm in diameter) vesicle comprising a membrane that encloses an internal space, and which is generated from said cell by direct or indirect manipulation such that said nanovesicle would not be produced by said producer cell without said manipulation.
- Appropriate manipulations of said producer cell include but are not limited to serial extrusion, treatment with alkaline solutions, sonication, or combinations thereof. The production of nanovesicles may, in some instances, result in the destruction of said producer cell.
- populations of nanovesicles are substantially free of vesicles that are derived from producer cells by way of direct budding from the plasma membrane or fusion of the late endosome with the plasma membrane.
- the nanovesicle comprises lipid or fatty acid and polypeptide, and optionally comprises a payload (e.g., a therapeutic agent), a receiver (e.g., a targeting moiety), a polynucleotide (e.g., a nucleic acid, RNA, or DNA), a sugar (e.g., a simple sugar, polysaccharide, or glycan) or other molecules.
- the nanovesicle once it is derived from a producer cell according to said manipulation, may be isolated from the producer cell based on its size, density, biochemical parameters, or a combination thereof.
- exosome refers to a cell-derived small (between 20-300 nm in diameter, more preferably 40-200 nm in diameter) vesicle comprising a membrane that encloses an internal space, and which is generated from said cell by direct plasma membrane budding or by fusion of the late endosome with the plasma membrane. Generally, production of exosomes does not result in the destruction of the producer cell.
- the exosome comprises lipid or fatty acid and polypeptide, and optionally comprises a payload (e.g., a therapeutic agent), a receiver (e.g., a targeting moiety), a polynucleotide (e.g., a nucleic acid, RNA, or DNA), a sugar (e.g., a simple sugar, polysaccharide, or glycan) or other molecules.
- a payload e.g., a therapeutic agent
- a receiver e.g., a targeting moiety
- a polynucleotide e.g., a nucleic acid, RNA, or DNA
- a sugar e.g., a simple sugar, polysaccharide, or glycan
- the exosome can be derived from a producer cell, and isolated from the producer cell based on its size, density, biochemical parameters, or a combination thereof.
- parent cell or “producer cell” include any cell from which an extracellular vesicle may be isolated. The terms also encompasses a cell that shares a protein, lipid, sugar, or nucleic acid component of the extracellular vesicle.
- a “parent cell” or “producer cell” may include a cell which serves as a source for the extracellular vesicle membrane.
- the terms “purify,” “purified,” and “purifying” or “isolate,” “isolated,” or “isolating” or “enrich,” “enriched” or “enriching” are used interchangeably and refer to the state of a population (e.g., a plurality of known or unknown amount and/or concentration) of desired extracellular vesicles, that have undergone one or more processes of purification, e.g., a selection or an enrichment of the desired extracellular vesicles composition, or alternatively a removal or reduction of residual biological products as described herein.
- a purified extracellular vesicles composition has no detectable undesired activity or, alternatively, the level or amount of the undesired activity is at or below an acceptable level or amount.
- a purified extracellular vesicle composition has an amount and/or concentration of desired extracellular vesicles at or above an acceptable amount and/or concentration.
- the purified extracellular vesicle composition is enriched as compared to the starting material (e.g., biological material collected from tissue, bodily fluid, or cell preparations) from which the composition is obtained.
- This enrichment may be by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99%, 99.999%, 99.9999%, or greater than 99.9999% as compared to the starting material.
- a “payload” as used herein is a therapeutic agent that acts on a target (e.g. a target cell) that is contacted with the extracellular vesicles.
- Payloads that may be introduced into a extracellular vesicles and/or a producer cell include therapeutic agents such as, nucleotides (e.g. nucleotides comprising a detectable moiety or a toxin or that disrupt transcription), nucleic acids (e.g. DNA or mRNA molecules that encode a polypepetide such as an enzyme, or RNA molecules that have regulatory function such as miRNA, dsDNA, lncRNA, siRNA), amino acids (e.g.
- the payload may comprise nucleotides, e.g. nucleotides that are labeled with a detectable or cytotoxic moiety (e.g. a radiolabel).
- Transgene or “exogenous nucleic acid” refers to a foreign or native nucleotide sequence that is introduced into an extracellular vesicle. Transgene and exogenous nucleic acid are used interchangeably herein and encompass recombinant nucleic acids.
- a “therapeutic agent” or “therapeutic molecule” includes a compound or molecule that, when present in an effective amount, produces a desired therapeutic effect, pharmacologic and/or physiologic effect on a subject in need thereof. It includes any compound, e.g., a small molecule drug, or a biologic (e.g., a polypeptide drug or a nucleic acid drug) that when administered to a subject has a measurable or conveyable effect on the subject, e.g., it alleviates or decreases a symptom of a disease, disorder or condition.
- a therapeutic agent or “therapeutic molecule” includes a compound or molecule that, when present in an effective amount, produces a desired therapeutic effect, pharmacologic and/or physiologic effect on a subject in need thereof. It includes any compound, e.g., a small molecule drug, or a biologic (e.g., a polypeptide drug or a nucleic acid drug) that when administered to a subject has a measurable
- compositions, carriers, diluents and reagents capable of administration to or upon a subject without the production of undesirable physiological effects to a degree that would prohibit administration of the composition.
- the term “pharmaceutical composition” refers to one or more of the compounds described herein, such as, e.g., an extracellular vesicles mixed or intermingled with, or suspended in one or more other chemical components, such as pharmaceutically acceptable carriers and excipients.
- a pharmaceutical composition is to facilitate administration of preparations of extracellular vesicles to a subject.
- the term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated value ⁇ 10%, ⁇ 5%, or ⁇ 1%. In certain embodiments, where applicable, the term “about” indicates the designated value(s) ⁇ one standard deviation of that value(s).
- Ranges recited herein are understood to be shorthand for all of the values within the range, inclusive of the recited endpoints.
- a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50.
- Extracellular vesicles can include, but are not limited to, an exosome, a nanovesicle, an apoptotic body, a microvesicle, a lysosome, an endosome, an enveloped virus, a viral vector, a liposome, a lipid nanoparticle, a micelle, a multilamellar structure, a revesiculated vesicle, or an extruded cell.
- Homogenization the application of shear and cavitation, can stress the vesicular structure resulting in many effects, including distortion to the phospholipid membrane and associated cytoskeleton leading to the creation of transient pores; and increase permeability, exposure of binding sites, and/or invagination of the surface.
- Homogenization may also lead to disaggregation of lipid rafts leading to increased permeability and membrane fluidity; formation of multilamellar bodies, both through invagination and disaggregation; conformational shifts in peripheral and transmembrane proteins that expose binding sites, alter surface properties, and enable the transmembrane passage of molecules; heat the vesicular membrane and alter permeability, fluidity, and diffusion; and/or denature proteins that permanently affect the structure of the membrane. Homogenization may also alter the surface properties of the molecule to be loaded or cause shifts in the chemical equilibria and local concentrations of molecules, leading to steeper concentration gradients. These effects may facilitate the loading of molecules into or onto vesicles, and improve the efficiency of loading diverse classes of molecules.
- any homogenization method that induces controlled injury may be used to load an agent, e.g. a payload molecule, receiver or surface marker into or onto an extracellular vesicle.
- the homogenization of the membrane of the producer cell or extracellular vesicles can be caused by, for example, pressure induced by mechanical strain or shear forces, subjecting the cell to deformation, constriction, rapid stretching, rapid compression, or pulse of high shear rate.
- the controlled injury leads to uptake of material, e.g., a payload, receiver or surface marker into the interior of the extracellular vesicles or the cytoplasm of the producer cell from the surrounding cell medium.
- vesicles may be homogenized using a microfluidizer.
- Microfluidizers may be purchased from commercial sources, such as the LV1 Microfluidizer made by Idex Corporation (Newton, Mass.) or the M110P homogenization module made by Microfluidics Corp (Westwood, Mass.)
- a microfluidizer consists of a fixed-geometry interaction chamber in which flow is driven by a pump.
- the incoming flow is split into two or more streams and the recombined at high velocity to create steep velocity and pressure gradients, shear, cavitation, and heating.
- the intensity of homogenization can be altered by changing the geometry of the interaction chamber, altering the temperature, changing the pressure, or processing the same material through the instrument multiple times.
- the pressure of the microfluidization can be from about 5,000 to 50,000 psi.
- the pressure of the microfluidization can be at least about 5,000 psi, 10,000 psi, 15,000 psi, 20,000 psi, 25,000 psi, 20,000 psi, 25,000 psi, 40,000 psi, 45,000 psi, or 50,000 psi.
- the pressure of the microfluidization can be between about 5,000 to 50,000 psi, 5,000 to 10,000 psi, 7,500 to 12,000 psi, 10,000 to 15,000 psi, 15,000 to 20,000 psi, 15,000-22,000, psi, 18,000-25,000 psi, 18,000-22,000 psi, 20,000 to 25,000 psi, 25,000 to 30,000 psi, 27,500 to 30,000 psi, 27,500 to 32,000 psi, 30,000 to 32,000 psi, 30,000 to 35,000 psi, 35,000 to 40,000 psi, 40,000 to 45,000 psi, or 45,000 to 50,000 psi.
- the pressure of the homogenization or microfluidization is about 10,000 psi, 20,000 psi, or 30,000 psi. In one embodiment, the pressure is between 10,000 and 30,000 psi.
- the homogenization or microfluidization may be a single pass or run, or comprise multiple passes or runs.
- the pressure of one or more of the multiple passes or runs may be that same for each pass.
- the pressure of the first pass can be about 10,000 psi and the pressure of the second pass can be about 10,000 psi; the pressure of the first pass can be about 20,000 psi and the pressure of the second pass can be about 20,000 psi; or the pressure of the first pass can be about 30,000 psi and the pressure of the second pass can be about 30,000 psi; or any of the microfluidization pressures disclosed herein.
- Multiple passes can be two or more passes, such as three passes, four passes, five passes, six passes, seven passes, eight passes, and so on.
- the pressure of one or more of the multiple passes or runs may be different.
- the pressure of the first pass can be about 10,000 psi and the pressure of the second pass can be about 20,000 psi; the pressure of the first pass can be about 20,000 psi and the pressure of the second pass can be about 30,000 psi; the pressure of the first pass can be about 30,000 psi and the pressure of the second pass can be about 20,000 psi; or the pressure of the first pass can be about 10,000 psi and the pressure of the second pass can be about 30,000 psi, or any combination of the microfluidization pressures disclosed herein.
- Multiple passes can be two or more passes, such as three passes, four passes, five passes, six passes, seven passes, eight passes, and so on.
- the buffer conditions of the solution of extracellular vesicles may also be altered to optimize homogenization and payload molecule loading.
- the buffer may be a phosphate buffered saline (PBS) with sucrose.
- PBS is a well-known buffer to those skilled in the art.
- the PBS buffer also comprises 0.5-5% sucrose.
- the buffer can comprise about 0.5-5%, 0.5-1%, 1-2%, 2-3%, 3-4%, 4-5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5% sucrose. Additional buffer modifications may also be used, such as shear protectants, viscosity modifiers, and/or solutes that affect vesicle structural properties.
- Excipients may also be added to improve the efficiency of the homogenization or microfluidization such as membrane softening materials and molecular crowding agents.
- Other modifications to the buffer may include specific pH ranges and/or concentrations of salts, organic solvents, small molecules, detergents, zwitterions, amino acids, polymers, and/or any combination of the above including multiple concentrations.
- the pH of the buffer may also be altered.
- the pH can be between 3-13, 3-5, 5-10, 7-8, 8-10, 10-13.
- the pH can be about 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 6.8, 7, 7.2, 7.4, 7.5, 7.6, 7.8, 8, 8.2, 8.4, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, or 13.
- the pH is between 3 and 13.
- the pH is between 7 and 8.
- the pH is 7.4.
- the temperature of the homogenization or microfluidization may be changed for optimization of loading the payload molecules.
- the temperature can be between about 15-90° C., 15-20° C., 20-25° C., 25-30° C., 30-35° C., 35-40° C., 45-50° C., 50-55° C., 55-60° C., 60-65° C., 65-70° C., 70-75° C., 75-80° C., 80-85° C., or 85-90° C.
- the temperature can be about 15° C., 20° C., 25° C., 27° C., 30° C., 32° C., 35° C., 40° C., 45° C., 50° C., 55° C., 60° C., 65° C., 70° C., 75° C., 80° C., 85° C., or 90° C.
- the temperature may be room temperature.
- the temperature is 15° C. to 80° C.
- the temperature is 70-80° C.
- the volume of the solution comprising extracellular vesicles to be homogenized or microfluidized may also be altered.
- the volume can be from about 1 ml to about 5000 ml, or more.
- the volume can be at least about 1-10 ml, 10-50 ml, 50-100 ml, 100-150 ml, 150-200 ml, 200-250 ml, 250-300 ml, 300-350 ml, 350-400 ml, 400-450 ml, 450-500 ml, 500-550 ml, 550-600 ml, 600-650 ml, 650-700 ml, 750-800 ml, 800-850 ml, 850-900 ml, 950-1000 ml, 1000-1500 ml, 1500-2000 ml, 2000-2500 ml, 2500-3000 ml, 3000-3500 ml, 3500-4000 ml, 4000-4500 ml, 45000-
- the volume can be at least about 1 ml, 10 ml, 20 ml, 30 ml, 40 ml, 50 ml, 60 ml, 70 ml, 80 ml, 90 ml, 100 ml, 150 ml, 200 ml, 250 ml, 300 ml, 350 ml, 400 ml, 450 ml, 500 ml, 550 ml, 600 ml, 650 ml, 700 ml, 750 ml, 800 ml, 850 ml, 900 ml, 950 ml, 1000 ml, 1500 ml, 2000 ml, 2500 ml, 3000 ml, 3500 ml, 4000 ml, 4500, ml or 5000 ml.
- the volume is less than a liter.
- the volume is more than a liter.
- the volume of the solution may be at least 1 ml.
- the extracellular vesicles may also be treated with additional technologies before or after homogenization.
- the vesicles are pre-treated before homogenization.
- the vesicles are post-treated after homogenization.
- the treatment may include a chemical treatment, such as acidic or basic buffers, or other chemical treatments not described herein.
- the extracellular vesicle may be modified with a single payload molecule or with a plurality of payload molecules. A detailed description of such payload molecules is disclosed below.
- the extracellular vesicles may be modified with a plurality of payload molecules.
- the payload molecules may be the same type or class of molecule, or a different type or class of molecule. Multiple types of payload molecules may be combined to produce vesicles modified with multivalent payload molecule cargoes.
- the vesicle can have two types, three types, four types, five types, six types, and so on.
- the payload molecules may be predominantly on the surface of the modified vesicle.
- the payload molecules may be predominantly inside the modified vesicle.
- the extracellular vesicles to be modified may be homogenized first and the payload molecules added to the homogenized vesicle solution.
- the extracellular vesicles and the payload molecules are mixed together and the mixture is homogenized.
- the homogenization may be applied in a batch mode, a semi-batch mode, or a continuous process. Either batch or continuous process may rely on feedback to control the homogenization or microfluidization parameters and/or terminate the process.
- Extracellular vesicles can be extracted from the supernatant of parent cells and demonstrate membrane and internal protein, lipid, and nucleic acid compositions that enable their efficient delivery to and interaction with recipient cells.
- Extracellular vesicles can be derived from parent cells that may include, but are not limited to, reticulocytes, erythrocytes, megakaryocytes, platelets, neutrophils, tumor cells, connective tissue cells, neural cells and stem cells.
- Suitable sources of extracellular vesicles include but are not limited to, cells isolated from subjects from patient-derived hematopoietic or erythroid progenitor cells, immortalized cell lines, or cells derived from induced pluripotent stem cells, optionally cultured and differentiated.
- Cell culture protocols can vary according to compositions of nutrients, growth factors, starting cell lines, culture period, and morphological traits by which the resulting cells are characterized.
- the samples comprising extracellular vesicles are derived from a plurality of donor cell types (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 50, 100, 500, 1000, 5000, or 10000 donor cell types) and are combined or pooled. Pooling may occur by mixing cell populations prior to extracellular vesicles extraction or by mixing isolated extracellular vesicles compositions from subsets of donor cell types. Parent cells may be irradiated or otherwise treated to affect the production rate and/or composition pattern of secreted extracellular vesicles prior to isolation.
- the extracellular vesicle comprises a membrane that forms a particle that has a diameter of between about 10-100 nm, 50-150 nm, 30-100 nm, 40-100 nm, 20-150 nm, 20-200 nm, 80-125 nm, 40-250 nm, 20-500 nm, or between about 10-1000 nm.
- the vesicle particle can have diameter of about 10, 150, 100, 120, 125, 130, 135, 140, 145, 150, 155, 160, 175, 200, 225, 250, 275, 300, 325, 250, 275, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, or 1000 nm.
- the membrane comprises lipids and fatty acids.
- the membrane comprises one or more of phospholipids, glycolipids, fatty acids, sphingolipids, phosphoglycerides, sterols, cholesterols, and phosphatidylserine.
- the membrane may comprise one or more polypeptides and one or more polysaccharides, such as glycans.
- the extracellular vesicle is generated by a producer cell (or parental cell), such as, e.g., a mammalian cell.
- the membrane of the extracellular vesicle comprises one or more molecules derived from the producer cell.
- the extracellular vesicle may be generated in a cell culture system and isolated, e.g. by separating the extracellular vesicle from the producer cell. Separation may be achieved by sedimentation.
- the extracellular vesicle can have a specific density between 0.5-2.0, 0.5-0.75, 0.5-1, 0.75-1.5, 0.75-2, 1-2, 1.5-2, and 0.9-1.1 kg/m 3 .
- the extracellular vesicle can have a specific density about 0.5, 0.75, 1, 1.25, 1.5, 1.75, or 2 kg/m 3 .
- the extracellular vesicle delivers the payload molecule to a target.
- the payload molecule is a therapeutic agent that acts on a target (e.g. a target cell) that is contacted with the extracellular vesicle. Contacting may occur, e.g. in vitro or in a subject.
- Payloads that may be introduced into an extracellular vesicle and/or a producer cell include therapeutic agents such as, nucleotides (e.g. nucleotides comprising a detectable moiety or a toxin or that disrupt transcription), nucleic acids (e.g.
- DNA or mRNA molecules that encode a polypepetide such as an enzyme, or RNA molecules that have regulatory function such as miRNA, dsDNA, lncRNA, siRNA), amino acids (e.g. amino acids comprising a detectable moiety or a toxin or that disrupt translation), polypeptides (e.g. enzymes), lipids, carbohydrates, and small molecules (e.g. small molecule drugs and toxins).
- the payload may comprise nucleotides, e.g. nucleotides that are labeled with a detectable or cytotoxic moiety (e.g. a radiolabel).
- the extracellular vesicle comprises nucleotides and/or polynucleotides (e.g. nucleic acids).
- the extracellular vesicle may comprise RNA, DNA, mRNA, miRNA, dsDNA, lncRNA, siRNA, or singular nucleotides.
- the nucleotides and polynucleotides are synthetic.
- an exogenous nucleic acid may be introduced into the extracellular vesicle and/or the producer cell.
- the nucleic acid is DNA that can be transcribed into an RNA (e.g.
- the nucleic acid is an RNA (e.g. an siRNA or mRNA) and in the case of an mRNA may be translated into a desired polypeptide.
- the extracellular vesicle comprises a nucleic acid, such as a RNA or DNA.
- the nucleic acid is delivered to a target cell as a payload.
- the target cell may transcribe a DNA payload into an RNA such as a siRNA.
- the cell may translate the mRNA into a polypeptide (e.g. therapeutic polypeptide).
- the target cell may also translate a delivered mRNA payload into a polypeptide.
- the producer cell comprises a nucleic acid that may be transcribed (e.g. a DNA may be transcribed into a siRNA or mRNA) and in case a mRNA is made the mRNA may be translated by the producer cell into a polypeptide.
- the producer cell may also be modified with a non-translatable RNA (e.g. siRNA or miRNA). In case a mRNA is transferred the producer cell may translate the mRNA into a polypeptide. Extracellular vesicles derived from the producer cell may then carry the non-translatable RNA, the transcribed RNA or the translated polypeptide as a payload.
- the nucleic acid payload is a modified nucleic acid.
- said modified nucleic acid is an siRNA or miRNA that is modified to additionally comprise one or more cholesterol molecules.
- the cholesterol modifications on the nucleic acid payloads may increase the association between the nucleic acid and the inner and/or outer membrane of the extracellular vesicles, therefore increasing the maximal loading capacity of the extracellular vesicles.
- said cholesterol is chemically conjugated to the 5′ end of the sense, or passenger strand of the siRNA or miRNA.
- said cholesterol is chemically conjugated to the 3′ end of the sense, or passenger strand of the siRNA or miRNA.
- said cholesterol is chemically conjugated to the 5′ end of the antisense, or guide strand of the siRNA or miRNA.
- said cholesterol is chemically conjugated to the 3′ end of the antisense, or guide strand of the siRNA or miRNA.
- the extracellular vesicles may interact with the target cell via membrane fusion and deliver payloads (e.g., therapeutic agents) in an extracellular vesicle composition to the surface or cytoplasm of a target cell.
- payloads e.g., therapeutic agents
- membrane fusion occurs between the extracellular vesicles and the plasma membrane of a target cell.
- membrane fusion occurs between the extracellular vesicles and an endosomal membrane of a target cell.
- the extracellular vesicles may be isolated from the producer cells. It is contemplated that all known manners of isolation of extracellular vesicles are deemed suitable for use herein.
- physical properties of extracellular vesicles may be employed to separate them from a medium or other source material, including separation on the basis of electrical charge (e.g., electrophoretic separation), size (e.g., filtration, molecular sieving, etc), density (e.g., regular or gradient centrifugation), Svedberg constant (e.g., sedimentation with or without external force, etc).
- isolation may be based on one or more biological properties, and include methods that may employ surface markers (e.g., for precipitation, reversible binding to solid phase, FACS separation, specific ligand binding, non-specific ligand binding, etc.).
- the extracellular vesicles may also be fused using chemical and/or physical methods, including PEG-induced fusion and/or ultrasonic fusion.
- Isolation (and enrichment) can be done in a general and non-selective manner (typically including serial centrifugation).
- isolation and enrichment can be done in a more specific and selective manner (e.g., using producer cell-specific surface markers).
- specific surface markers may be used in immunoprecipitation, FACS sorting, affinity purification, bead-bound ligands for magnetic separation etc.
- isolation can be done by affinity purification.
- the extracellular vesicle can be purified by binding a population comprising extracellular vesicles to a resin, said resin comprising a plurality of ligands that have specific affinity for one or more target proteins on the surface of the extracellular vesicle.
- the one or more target protein may be a tetraspanin (e.g., CD63, CD81 and/or CD9), an EWI protein/immunoglobulin superfamily member (e.g., PTGFRN, IGSF8 and/or IGSF3), an integrin (e.g., ITGB1 and/or ITGA4), an ATP transporter protein (e.g., ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3 and/or ATP2B4), SLC3A2, BSG, or CD98hc.
- the target protein may additionally be the immunomodulating component that is displayed on the surface of the exosomes.
- size exclusion chromatography can be utilized to isolate the extracellular vesicles. Size exclusion chromatography techniques are known in the art. Exemplary, non-limiting techniques are provided herein.
- a void volume fraction is isolated and comprises the extracellular vesicles of interest.
- the extracellular vesicles can be further isolated after chromatographic separation by centrifugation techniques (of one or more chromatography fractions), as is generally known in the art.
- density gradient centrifugation can be utilized to further isolate the extracellular vesicles.
- the producer cell-derived extracellular vesicles can be separated from non-producer cell-derived extracellular vesicles by immunosorbent capture using an antigen antibody specific for the producer cell.
- the isolation of extracellular vesicles may involve combinations of methods that include, but are not limited to, differential centrifugation, size-based membrane filtration, concentration and/or rate zonal centrifugation.
- Particle size may be quantified after the extracellular vesicles are isolated using any appropriate technique, including dynamic light scattering or nanoparticle tracking analysis.
- the diameter of the extracellular vesicles in a population can also be described using particle size distribution (D values).
- D values reflect the mass of the extracellular vesicles in a population as a percentage when the particles are arranged on an ascending mass basis.
- the D10 value is the diameter at which 10% of the extracellular vesicles population mass is comprised of extracellular vesicles less than the indicated diameter value.
- the population of extracellular vesicles is comprised mainly of vesicles larger than the indicated diameter value.
- the D50 value is the diameter at which 50% of the extracellular vesicles population mass is comprised of vesicles less than the indicated diameter value and 50% of the extracellular vesicles population mass is comprised of vesicles larger than the indicated value. In such a case, the population of extracellular vesicles is comprised equally of vesicles larger than the indicated diameter value and smaller than the indicated diameter.
- the D90 value is the diameter at which 90% of the extracellular vesicles population mass is comprised of extracellular vesicles less than the indicated diameter value. In this case, the population of extracellular vesicles is comprised mainly of vesicles smaller than the indicated diameter value.
- Extracellular vesicles may comprise payloads such as peptides, proteins, DNA, RNA, siRNA, and other macromolecules and small therapeutic molecules.
- the payload is transferred to a producer cell by applying controlled injury to the cell for a predetermined amount of time in order to cause perturbations in the cell membrane such that the payload can be delivered to the inside of the cell (e.g., cytoplasm).
- the payload is transferred to a extracellular vesicles isolated from a producer cell by applying controlled injury to the extracellular vesicles for a predetermined amount of time in order to cause perturbations in the complex membrane such that the payload can be delivered to the inside of the extracellular vesicles.
- the payload of the extracellular vesicles may be loaded within the membrane or interior portion of the extracellular vesicles.
- the payload may be a therapeutic agent selected from a variety of known small molecule pharmaceuticals.
- the payload may be a therapeutic agent selected from a variety of macromolecules, such as, e.g., an inactivating peptide nucleic acid (PNA), an RNA or DNA oligonucleotide aptamer, an interfering RNA (iRNA), a peptide, or a protein.
- PNA inactivating peptide nucleic acid
- iRNA interfering RNA
- the payload that may be delivered to a target by a extracellular vesicles includes, but is not limited to, RNA, DNA, siRNA, mRNA, lncRNA, iRNA, polypeptides, enzymes, cyotkines, antibodies, antibody fragments, small molecules, chemotherapeutics, metals, viral particles, imaging agents, and plasmids.
- the payload of the extracellular vesicles is a nucleic acid molecule, e.g. mRNA or DNA
- the extracellular vesicles targets the payload to the cytoplasm of the recipient or target cell, such that the nucleic acid molecule can be translated (if mRNA) or transcribed and translated (if DNA) and thus produce the polypeptide encoded by the payload nucleic acid molecule within the target cell.
- the polypeptide encoded by the payload nucleic acid molecule is secreted by the target cell, thus modulating the systemic concentration or amount of the polypeptide encoded by the payload nucleic acid molecule in the subject.
- the polypeptide encoded by the payload nucleic acid molecule is not secreted by the target cell, thus modulating the intracellular concentration or amount of the polypeptide encoded by the payload nucleic acid molecule in the subject.
- the polypeptide encoded by the payload nucleic acid molecule is toxic to the target cell or to other cell or tissue in the subject, e.g. toxic to a cancer cell.
- the polypeptide encoded by the payload nucleic acid molecule is not toxic to the target cell or other cell or tissue in the subject, e.g. is therapeutically beneficial or corrects a disease phenotype.
- the payload of the extracellular vesicles may be a membrane protein delivered to the plasma membrane or endosomal membrane of the recipient cell.
- Extracellular vesicles may comprise two or more payloads, including mixtures, fusions, combinations and conjugates, of atoms, molecules, etc. as disclosed herein, for example including but not limited to, a nucleic acid combined with a polypeptide; two or more polypeptides conjugated to each other; a protein conjugated to a biologically active molecule (which may be a small molecule such as a prodrug); and the like.
- Suitable payloads include, without limitation, pharmacologically active drugs and genetically active molecules, including antineoplastic agents, anti-inflammatory agents, hormones or hormone antagonists, ion channel modifiers, and neuroactive agents.
- suitable payloads of therapeutic agents include those described in, “The Pharmacological Basis of Therapeutics,” Goodman and Gilman, McGraw-Hill, New York, N.Y., (1996), Ninth edition, under the sections: Drugs Acting at Synaptic and Neuroeffector Junctional Sites; Drugs Acting on the Central Nervous System; Autacoids: Drug Therapy of Inflammation; Water, Salts and Ions; Drugs Affecting Renal Function and Electrolyte Metabolism; Cardiovascular Drugs; Drugs Affecting Gastrointestinal Function; Drugs Affecting Uterine Motility; Chemotherapy of Parasitic Infections; Chemotherapy of Microbial Diseases; Chemotherapy of Neoplastic Diseases; Drugs Used for Immunosuppression; Drugs Acting
- the payload is a therapeutic agent, such as a small molecule drug or a large molecule biologic.
- Large molecule biologics include, but are not limited to, a protein, polypeptide, or peptide, including, but not limited to, a structural protein, an enzyme, a cytokine (such as an interferon and/or an interleukin), a polyclonal or monoclonal antibody, or an effective part thereof, such as an Fv fragment, which antibody or part thereof, may be natural, synthetic or humanized, a peptide hormone, a receptor, or a signaling molecule.
- the protein payload is a Cas9 protein, a TALEN, a zinc finger nuclease, or other component of a genome-editing complex.
- Intrabodies Large molecule biologics are immunoglobulins, antibodies, Fv fragments, etc., that are capable of binding to antigens in an intracellular environment. These types of molecules are known as “intrabodies” or “intracellular antibodies.”
- An “intracellular antibody” or an “intrabody” includes an antibody that is capable of binding to its target or cognate antigen within the environment of a cell, or in an environment that mimics an environment within the cell. Selection methods for directly identifying such “intrabodies” include the use of an in vivo two-hybrid system for selecting antibodies with the ability to bind to antigens inside mammalian cells. Such methods are described in PCT/GB00/00876, incorporated herein by reference.
- Large molecule biologics include but is not limited to, at least one of a protein, a polypeptide, a peptide, a nucleic acid, a virus, a virus-like particle, an amino acid, an amino acid analogue, a modified amino acid, a modified amino acid analogue, a steroid, a proteoglycan, a lipid and a carbohydrate or a combination thereof (e.g., chromosomal material comprising both protein and DNA components or a pair or set of effectors, wherein one or more convert another to active form, for example catalytically).
- chromosomal material comprising both protein and DNA components or a pair or set of effectors, wherein one or more convert another to active form, for example catalytically.
- a large molecule biologic may include a nucleic acid, including, but not limited to, an oligonucleotide or modified oligonucleotide, an antisense oligonucleotide or modified antisense oligonucleotide, an aptamer, a cDNA, genomic DNA, an artificial or natural chromosome (e.g., a yeast artificial chromosome) or a part thereof, RNA, including an siRNA, a shRNA, mRNA, tRNA, rRNA or a ribozyme, or a peptide nucleic acid (PNA); a virus or virus-like particles; a nucleotide or ribonucleotide or synthetic analogue thereof, which may be modified or unmodified.
- Said modification may be a lipophilic modification including addition of a cholesterol molecule, myristoylation, PEGylation, and/or palmitoylation.
- the large molecule biologic can also be an amino acid or analogue thereof, which may be modified or unmodified or a non-peptide (e.g., steroid) hormone; a proteoglycan; a lipid; or a carbohydrate. If the large molecule biologic is a polypeptide, it can be loaded directly into a producer cell according to the methods described herein. Alternatively, an exogenous nucleic acid encoding a polypeptide, which sequence is operatively linked to transcriptional and translational regulatory elements active in a producer cell at a target site, may be loaded.
- a non-peptide e.g., steroid
- Small molecules including inorganic and organic chemicals, may also be used as payloads of the extracellular vesicles described herein.
- the small molecule is a pharmaceutically active agent.
- pharmaceutically active agents include, but are not limited to, antibiotics, anti-inflammatory drugs, angiogenic or vasoactive agents, growth factors and chemotherapeutic (anti-neoplastic) agents (e.g., tumour suppressers).
- the payload molecule comprises an agonist or activator of stimulator of interferon genes (STING).
- STING agonist may be a cyclic dinucleotide (CDN).
- CDNs including but not limited to cyclic diguanylate monophosphate (c-di-GMP), are described in Nature 2011, DOI: 10.1038/nature10429 and Nat. Chem. Biol. 2014, DOI: 10.1038/nchembio.1661.
- the STING agonist may be a small molecule agonist.
- a payload may be expressed by a target cell from a transgene or mRNA introduced into a extracellular vesicles by electroporation, chemical or polymeric transfection, viral transduction, mechanical membrane disruption, or other method when the target cell is contacted with the extracellular vesicles.
- the exogenous nucleic acid is an RNA molecule, or a DNA molecule that encodes for an RNA molecule, that silences or represses the expression of a target gene.
- the molecule can be a small interfering RNA (siRNA), an antisense RNA molecule, or a short hairpin RNA (shRNA) molecule.
- compositions comprising extracellular vesicles that are suitable for administration to a subject.
- the pharmaceutical compositions generally comprise a plurality of extracellular vesicles and a pharmaceutically-acceptable excipient or carrier in a form suitable for administration to a subject.
- Pharmaceutically-acceptable excipients or carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions comprising a plurality of extracellular vesicles. (See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 18th ed. (1990)).
- the pharmaceutical compositions are generally formulated sterile and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.
- GMP Good Manufacturing Practice
- the pharmaceutical composition comprises one or more therapeutic agents and the extracellular vesicles described herein.
- the extracellular vesicles are co-administered with of one or more separate therapeutic agents, wherein co-administration includes administration of the separate therapeutic agent before, after or concurrent with administration of the extracellular vesicles.
- compositions include excipients that are generally safe (GRAS), non-toxic, and desirable, including excipients that are acceptable for veterinary use as well as for human pharmaceutical use.
- GRAS generally safe
- excipients that are acceptable for veterinary use as well as for human pharmaceutical use.
- Examples of carriers or diluents include, but are not limited to, water, saline, Ringer's solutions, dextrose solution, and 5% human serum albumin.
- the use of such media and compounds for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or compound is incompatible with the extracellular vesicles described herein, use thereof in the compositions is contemplated. Supplementary therapeutic agents may also be incorporated into the compositions.
- a pharmaceutical composition is formulated to be compatible with its intended route of administration.
- the extracellular vesicles can be administered by parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intradermal, transdermal, rectal, intracranial, intraperitoneal, intranasal; intramuscular route or as inhalants.
- the pharmaceutical composition comprising extracellular vesicles is administered intravenously, e.g. by injection.
- the extracellular vesicles can optionally be administered in combination with other therapeutic agents that are at least partly effective in treating the disease, disorder or condition for which the extracellular vesicles are intended.
- Solutions or suspensions can include the following components: a sterile diluent such as water, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and compounds for the adjustment of tonicity such as sodium chloride or dextrose.
- the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- compositions suitable for injectable use include sterile aqueous solutions (if water soluble) or dispersions and sterile powders.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition is generally sterile and fluid to the extent that easy syringeability exists.
- the carrier can be a solvent or dispersion medium containing, e.g., water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, e.g., by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal compounds, e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic compounds e.g., sugars, polyalcohols such as manitol, sorbitol, sodium chloride can be added to the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition a compound which delays absorption, e.g., aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the extracellular vesicles in an effective amount and in an appropriate solvent with one or a combination of ingredients enumerated herein, as desired.
- dispersions are prepared by incorporating the extracellular vesicles into a sterile vehicle that contains a basic dispersion medium and any desired other ingredients.
- methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- the extracellular vesicles can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner to permit a sustained or pulsatile release of the extracellular vesicles.
- compositions comprising extracellular vesicles can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, e.g., for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the modified extracellular vesicles are formulated into ointments, salves, gels, or creams as generally known in the art.
- Example 1 Microfluidization for Loading Exosomes with siRNA
- Exosomes were purified chromatographically from a single-use bioreactor (SUB) and formulated in PBS-Sucrose buffer (1.8 mM KH 2 PO 4 , 10 mM Na 2 HPO 4 , 137 mM NaCl, 2.7 mM KCl, 5% w/v sucrose, pH 7.4). Exosomes were mixed with an siRNA targeting kras G12D at a final concentration of 2 ⁇ M siRNA and 1 ⁇ 10 11 particles per mL in a 1 ⁇ PBS, ⁇ 1% sucrose buffer.
- PBS-Sucrose buffer 1.8 mM KH 2 PO 4 , 10 mM Na 2 HPO 4 , 137 mM NaCl, 2.7 mM KCl, 5% w/v sucrose, pH 7.4
- Exosomes were mixed with an siRNA targeting kras G12D at a final concentration of 2 ⁇ M siRNA and 1 ⁇ 10 11 particles per mL in a 1 ⁇ P
- Loading reactions were performed at a 1.0 mL scale, and processed in duplicate over a Microfluidics M110P homogenization module equipped with a F12Y (75 ⁇ m) interaction chamber (Microfludics, Westwood, Mass.). Reactions were held at 20-25° C. by using a heat-exchanger coil configured to the outlet of the interaction chamber submerged in water. Upon processing, samples were filtered using a 0.45 ⁇ m PVDF filter and stored at 4° C. Process conditions were screened in a single-pass manner at 1 ⁇ 10 4 , 2 ⁇ 10 4 , and 3 ⁇ 10 4 psi. Process controls were run in addition to the loading reactions. The entire experimental matrix is shown in Table 1.
- NTA nanoparticle tracking analysis
- samples were filtered using a 0.45 ⁇ m polypropylene filter plate, and added to Panc-1 cells to assay kras knockdown using an mRNA knockdown qPCR assay.
- the relative kras expression of treated and control cells are shown in FIG. 1 . Positive (non-transfected Panc-1 cells) and negative controls (Lipofectamine-transfected Panc-1 with a kras G12D siRNA) were performed in parallel.
- the homogenized vesicle samples showed greater knockdown of kras expression as compared to extracellular vesicles (EV), siRNA only, or Mixing control samples.
- Mixing controls show similar gene expression to the negative control, and reagent only process controls (siRNA only) show normal gene expression.
- the 3 ⁇ 10 4 reagent controls showed knockdown when processed independently through the LV-1.
- LV-1 Microfludizer When vesicles and siRNA were processed through the LV-1 Microfludizer, a pressure-dependent gene-knockdown effect is observed—with the greatest knockdown seen at a single-pass at the highest concentration of 3 ⁇ 10 4 psi.
- Example 2 To determine conditions that maximized siRNA loading of exosomes, microfluidic homogenization was carried out as in Example 1 at varying concentrations of siRNA. Exosome samples were processed with kras G12D siRNAs at 0.5 ⁇ M, 2 ⁇ M, or 8 ⁇ M final concentrations. The products from each run were added to cultured Panc-1 cells at concentrations of 100 EV/cell, 500 EV/cell, 1 ⁇ 10 3 EV/cell or 1 ⁇ 10 4 EV/cell. As a positive control, Panc-1 cells were transfected with the kras G12D siRNA using Lipofectamine. As shown in FIG. 2 , there was a concentration-dependent and dosage-dependent increase in KRAS mRNA knockdown with 8 ⁇ M siRNA and 1 ⁇ 10 4 exosomes resulting in the greatest knockdown.
- Another method of loading exosomes with siRNA molecules is to use siRNA duplexes that are covalently fused to a cholesterol moiety. Cholesterol-conjugated siRNAs can associate with the exosome membrane through lipid-lipid interactions between the cholesterol molecule and the phospholipids of the exosome membrane. This loading strategy can increase effective concentration of loaded exosomes and allow for delivery of more siRNA molecules to a recipient cell.
- exosomes were loaded as in Example 1 with unmodified kras G12D siRNA or a cholesterol-tagged version of the same miRNA.
- these siRNAs were mixed with exosomes without microfluidic homogenization. All samples were processed at either 10,000 psi or 20,000 psi and added to Panc-1 cells at a concentration of 1 ⁇ 10 4 exosomes per cell.
- FIG. 3 at 30,000 psi both the unmodified and cholesterol-tagged siRNAs resulted in significant knockdown of the kras G12D transcript, while none of the mixing controls altered the levels of the transcript.
- the cholesterol-tagged siRNA could efficiently knock down the transcript at 20,000 psi, while there was very modest knockdown of the transcript at 20,000 psi with the unmodified siRNA.
- RNA profiles were measured for siRNAs exposed to repeated rounds of homogenization.
- siRNA FIG. 4A
- cholesterol-tagged siRNA FIG. 4B
- FIGS. 4A and 4B both RNA species were diluted by serial rounds of homogenization, but the shape of the chromatographic trace was not changed, indicating that the structure of the siRNA was resistant to multiple rounds of high-pressure microfluidic processing.
Abstract
Description
- This application claims the benefit of U.S. Provisional Patent Application No. 62/588,143, filed Nov. 17, 2017, the disclosure of which is incorporated by reference in its entirety.
- There is a need in the field for improved methods and compositions for delivering therapeutic agents to cells. The therapeutic properties of extracellular vesicles can be enhanced by the complexation of a molecule or molecules in a process referred to as loading. Loading represents the encapsulation, partial engulfment, and/or external association of a cargo molecule with the vesicle or vesicles. Methods that facilitate the loading of molecules into or onto vesicles can improve efficiency and enable the loading of diverse classes of molecules. Homogenization, the application of shear and cavitation, can be applied simultaneously to both vesicles and the desired payload to promote loading of the payload into and/or on to the vesicle.
- Homogenization, including microfluidization (a branded from of homogenization) has been previously employed for nanoencapsulation and loading of liposomes but has not been used for the loading of vesicles. Provided herein are methods for loading exosomes with therapeutic agents, and the exosomes created by those methods.
- Disclosed herein are methods for producing an isolated extracellular vesicle for delivery of a payload molecule comprising modifying an extracellular vesicle with a payload molecule via homogenization, isolating the modified extracellular vesicle containing the payload molecule, and optionally formulating the isolated modified extracellular vesicle into a pharmaceutical composition. In one embodiment, the vesicle is an exosome, a nanovesicle, an apoptotic body, a microvesicle, a lysosome, an endosome, an enveloped virus, a viral vector, a liposome, a lipid nanoparticle, a micelle, a multilamellar structure, a revesiculated vesicle, or an extruded cell. In another embodiment the payload molecule is a therapeutic molecule. In another embodiment, the vesicle is modified with a plurality of payload molecules.
- In some embodiments, the homogenization is microfluidization. In some embodiments, the microfluidization is a single pass. In other embodiments, the microfluidization is multiple passes. In some embodiments, the pressure of the microfluidization is performed between 10,000 to 30,000 pounds per square inch (psi). In one embodiment, the microfluidization is 10,000 psi. In one embodiment, the microfluidization is 20,000 psi. In one embodiment, the microfluidization is 30,000 psi. In some embodiments, the pressure is the same in multiple passes. In other embodiments, the pressure is different in multiple passes.
- In some embodiments, the vesicle is in buffered solution. In one embodiment, the solution is between a
pH 3 and 13. In another embodiment, the pH of the solution is between 7 and 8. In a further embodiment, the pH of the solution is 7.4. In some embodiments, the buffered solution comprises phosphate buffered saline and 0.5-5% sucrose. - In some embodiments, the volume of the microfluidization is less than a liter. In other embodiments, the volume of the microfluidization is more than a liter. In another embodiment, the volume of the microfluidization is at least 1 ml.
- In some embodiments, the microfluidization is performed at 15° C. to 80° C. In another embodiment, the microfluidization is performed at room temperature. In some embodiments, the microfluidization is performed at 70-80° C.
- In one embodiment the payload is siRNA, miRNA, antisense RNA, DNA, a plasmid, mRNA, tRNA, a protein, a carbohydrate, a lipid, a small molecule drug, a toxin, an antibody, a recombinant protein, a viral vector, or a vaccine. In another embodiment, the payload is siRNA. In certain embodiments, the payload is a modified nucleic acid. In some embodiments, said modified nucleic acid is an siRNA or miRNA that is modified to additionally comprise one or more cholesterol molecules. In some embodiments, said cholesterol is chemically conjugated to the 5′ end of the sense, or passenger strand of the siRNA or miRNA. In some embodiments, said cholesterol is chemically conjugated to the 3′ end of the sense, or passenger strand of the siRNA or miRNA. In some embodiments, said cholesterol is chemically conjugated to the 5′ end of the antisense, or guide strand of the siRNA or miRNA. In some embodiments, said cholesterol is chemically conjugated to the 3′ end of the antisense, or guide strand of the siRNA or miRNA.
- In some embodiments, a solution comprising the vesicle and the payload are first mixed and the mixture is homogenized. In some embodiments, a solution comprising the vesicle is homogenized first and the payload is added to the homogenized vesicle solution.
- In some embodiments, the vesicle is modified with a plurality of payload molecules.
- In one embodiment, the payload molecules are predominantly on the surface of the modified vesicle. In another embodiment, the payload molecules are predominantly inside the modified vesicle.
- In some embodiments, the vesicle in solution is both homogenized and treated with another technology for loading the payload molecules. In one embodiment, the additional treatment is a chemical treatment. In one embodiment, vesicle is post-treated after homogenization. In another embodiment, the vesicle is pre-treated before homogenization.
- The vesicles may be homogenized in a batch, a semi-batch, or a continuous process.
-
FIG. 1 shows the qPCR results from kras gene knockdown cell based assay in Panc-1 cells as a function of shear pressure. The left bar shows samples homogenized at 10,000 psi, the middle bar shows the samples homogenized at 20,000 psi, and the right bar shows the samples homogenized at 30,000 psi. -
FIG. 2 shows the qPCR results from kras gene knockdown cell based assay in Panc-1 cells as a function of siRNA concentration. -
FIG. 3 shows the qPCR results from kras gene knockdown cell based assay in Panc-1 cells using unmodified siRNA and cholesterol-tagged siRNA loaded in exosomes by microfluidic homogenization. -
FIGS. 4A-B show the anion exchange chromatogram profile of unmodified siRNA (4A) and cholesterol-tagged siRNA (4B) after repeated rounds of microfluidic homogenization. -
FIGS. 5A-B show the results from measuring the diameter of purified exosomes after repeated rounds of microfluidic homogenization as determined by size exclusion chromatography (5A) and nanoparticle tracking assay (5B). - Terms used in the claims and specification are defined as set forth below unless otherwise specified.
- As used herein, the term “extracellular vesicle” refers to a cell-derived vesicle comprising a membrane that encloses an internal space. Extracellular vesicles comprise all membrane-bound vesicles that have a smaller diameter than the cell from which they are derived. Generally extracellular vesicles range in diameter from 20 nm to 1000 nm, and may comprise various macromolecular cargo either within the internal space, displayed on the external surface of the extracellular vesicle, and/or spanning the membrane. Said cargo may comprise nucleic acids, proteins, carbohydrates, lipids, small molecules, and/or combinations thereof. By way of example and without limitation, extracellular vesicles include apoptotic bodies, fragments of cells, vesicles derived from cells by direct or indirect manipulation (e.g., by serial extrusion or treatment with alkaline solutions), vesiculated organelles, and vesicles produced by living cells (e.g., by direct plasma membrane budding or fusion of the late endosome with the plasma membrane). Extracellular vesicles may be derived from a living or dead organism, explanted tissues or organs, and/or cultured cells.
- As used herein, the term “nanovesicle” refers to a cell-derived small (between 20-250 nm in diameter, more preferably 30-150 nm in diameter) vesicle comprising a membrane that encloses an internal space, and which is generated from said cell by direct or indirect manipulation such that said nanovesicle would not be produced by said producer cell without said manipulation. Appropriate manipulations of said producer cell include but are not limited to serial extrusion, treatment with alkaline solutions, sonication, or combinations thereof. The production of nanovesicles may, in some instances, result in the destruction of said producer cell. Preferably, populations of nanovesicles are substantially free of vesicles that are derived from producer cells by way of direct budding from the plasma membrane or fusion of the late endosome with the plasma membrane. The nanovesicle comprises lipid or fatty acid and polypeptide, and optionally comprises a payload (e.g., a therapeutic agent), a receiver (e.g., a targeting moiety), a polynucleotide (e.g., a nucleic acid, RNA, or DNA), a sugar (e.g., a simple sugar, polysaccharide, or glycan) or other molecules. The nanovesicle, once it is derived from a producer cell according to said manipulation, may be isolated from the producer cell based on its size, density, biochemical parameters, or a combination thereof.
- As used herein, the term “exosome” refers to a cell-derived small (between 20-300 nm in diameter, more preferably 40-200 nm in diameter) vesicle comprising a membrane that encloses an internal space, and which is generated from said cell by direct plasma membrane budding or by fusion of the late endosome with the plasma membrane. Generally, production of exosomes does not result in the destruction of the producer cell. The exosome comprises lipid or fatty acid and polypeptide, and optionally comprises a payload (e.g., a therapeutic agent), a receiver (e.g., a targeting moiety), a polynucleotide (e.g., a nucleic acid, RNA, or DNA), a sugar (e.g., a simple sugar, polysaccharide, or glycan) or other molecules. The exosome can be derived from a producer cell, and isolated from the producer cell based on its size, density, biochemical parameters, or a combination thereof.
- As used herein, the terms “parent cell” or “producer cell” include any cell from which an extracellular vesicle may be isolated. The terms also encompasses a cell that shares a protein, lipid, sugar, or nucleic acid component of the extracellular vesicle. For example, a “parent cell” or “producer cell” may include a cell which serves as a source for the extracellular vesicle membrane.
- As used herein, the terms “purify,” “purified,” and “purifying” or “isolate,” “isolated,” or “isolating” or “enrich,” “enriched” or “enriching” are used interchangeably and refer to the state of a population (e.g., a plurality of known or unknown amount and/or concentration) of desired extracellular vesicles, that have undergone one or more processes of purification, e.g., a selection or an enrichment of the desired extracellular vesicles composition, or alternatively a removal or reduction of residual biological products as described herein. In some embodiments, a purified extracellular vesicles composition has no detectable undesired activity or, alternatively, the level or amount of the undesired activity is at or below an acceptable level or amount. In other embodiments, a purified extracellular vesicle composition has an amount and/or concentration of desired extracellular vesicles at or above an acceptable amount and/or concentration. In other embodiments, the purified extracellular vesicle composition is enriched as compared to the starting material (e.g., biological material collected from tissue, bodily fluid, or cell preparations) from which the composition is obtained. This enrichment may be by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99%, 99.999%, 99.9999%, or greater than 99.9999% as compared to the starting material.
- A “payload” as used herein is a therapeutic agent that acts on a target (e.g. a target cell) that is contacted with the extracellular vesicles. Payloads that may be introduced into a extracellular vesicles and/or a producer cell include therapeutic agents such as, nucleotides (e.g. nucleotides comprising a detectable moiety or a toxin or that disrupt transcription), nucleic acids (e.g. DNA or mRNA molecules that encode a polypepetide such as an enzyme, or RNA molecules that have regulatory function such as miRNA, dsDNA, lncRNA, siRNA), amino acids (e.g. amino acids comprising a detectable moiety or a toxin or that disrupt translation), polypeptides (e.g. enzymes), lipids, carbohydrates, and small molecules (e.g. small molecule drugs and toxins). The payload may comprise nucleotides, e.g. nucleotides that are labeled with a detectable or cytotoxic moiety (e.g. a radiolabel).
- “Transgene” or “exogenous nucleic acid” refers to a foreign or native nucleotide sequence that is introduced into an extracellular vesicle. Transgene and exogenous nucleic acid are used interchangeably herein and encompass recombinant nucleic acids.
- A “therapeutic agent” or “therapeutic molecule” includes a compound or molecule that, when present in an effective amount, produces a desired therapeutic effect, pharmacologic and/or physiologic effect on a subject in need thereof. It includes any compound, e.g., a small molecule drug, or a biologic (e.g., a polypeptide drug or a nucleic acid drug) that when administered to a subject has a measurable or conveyable effect on the subject, e.g., it alleviates or decreases a symptom of a disease, disorder or condition.
- The term “pharmaceutically-acceptable” and grammatical variations thereof, refers to compositions, carriers, diluents and reagents capable of administration to or upon a subject without the production of undesirable physiological effects to a degree that would prohibit administration of the composition.
- As used herein, the term “pharmaceutical composition” refers to one or more of the compounds described herein, such as, e.g., an extracellular vesicles mixed or intermingled with, or suspended in one or more other chemical components, such as pharmaceutically acceptable carriers and excipients. One purpose of a pharmaceutical composition is to facilitate administration of preparations of extracellular vesicles to a subject.
- The term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated value ±10%, ±5%, or ±1%. In certain embodiments, where applicable, the term “about” indicates the designated value(s) ±one standard deviation of that value(s).
- It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.
- Ranges recited herein are understood to be shorthand for all of the values within the range, inclusive of the recited endpoints. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50.
- Methods of the Invention
- Methods of Loading Extracellular Vesicles
- Described herein are methods for producing modified extracellular vesicles via mechanical shear such as homogenization and pharmaceutical preparations thereof. Extracellular vesicles can include, but are not limited to, an exosome, a nanovesicle, an apoptotic body, a microvesicle, a lysosome, an endosome, an enveloped virus, a viral vector, a liposome, a lipid nanoparticle, a micelle, a multilamellar structure, a revesiculated vesicle, or an extruded cell.
- Homogenization, the application of shear and cavitation, can stress the vesicular structure resulting in many effects, including distortion to the phospholipid membrane and associated cytoskeleton leading to the creation of transient pores; and increase permeability, exposure of binding sites, and/or invagination of the surface. Homogenization may also lead to disaggregation of lipid rafts leading to increased permeability and membrane fluidity; formation of multilamellar bodies, both through invagination and disaggregation; conformational shifts in peripheral and transmembrane proteins that expose binding sites, alter surface properties, and enable the transmembrane passage of molecules; heat the vesicular membrane and alter permeability, fluidity, and diffusion; and/or denature proteins that permanently affect the structure of the membrane. Homogenization may also alter the surface properties of the molecule to be loaded or cause shifts in the chemical equilibria and local concentrations of molecules, leading to steeper concentration gradients. These effects may facilitate the loading of molecules into or onto vesicles, and improve the efficiency of loading diverse classes of molecules.
- Generally, any homogenization method that induces controlled injury may be used to load an agent, e.g. a payload molecule, receiver or surface marker into or onto an extracellular vesicle. The homogenization of the membrane of the producer cell or extracellular vesicles can be caused by, for example, pressure induced by mechanical strain or shear forces, subjecting the cell to deformation, constriction, rapid stretching, rapid compression, or pulse of high shear rate. The controlled injury leads to uptake of material, e.g., a payload, receiver or surface marker into the interior of the extracellular vesicles or the cytoplasm of the producer cell from the surrounding cell medium.
- Many different homogenization instruments are available, including microfluidizers, French Press, high pressure homogenizers, bead mills, rotary blenders and rotor/stator devices. In some embodiments described herein, vesicles may be homogenized using a microfluidizer. Microfluidizers may be purchased from commercial sources, such as the LV1 Microfluidizer made by Idex Corporation (Newton, Mass.) or the M110P homogenization module made by Microfluidics Corp (Westwood, Mass.)
- A microfluidizer consists of a fixed-geometry interaction chamber in which flow is driven by a pump. The incoming flow is split into two or more streams and the recombined at high velocity to create steep velocity and pressure gradients, shear, cavitation, and heating. The intensity of homogenization can be altered by changing the geometry of the interaction chamber, altering the temperature, changing the pressure, or processing the same material through the instrument multiple times. There is also a complex interaction with the concentration of the incoming material, buffer composition, and the physiochemical properties of the solution, emulsion, or suspension.
- Several parameters may affect loading of the payload molecule, including pressure, temperature, number of homogenization passes, and buffer conditions. The pressure of the microfluidization can be from about 5,000 to 50,000 psi. The pressure of the microfluidization can be at least about 5,000 psi, 10,000 psi, 15,000 psi, 20,000 psi, 25,000 psi, 20,000 psi, 25,000 psi, 40,000 psi, 45,000 psi, or 50,000 psi. The pressure of the microfluidization can be between about 5,000 to 50,000 psi, 5,000 to 10,000 psi, 7,500 to 12,000 psi, 10,000 to 15,000 psi, 15,000 to 20,000 psi, 15,000-22,000, psi, 18,000-25,000 psi, 18,000-22,000 psi, 20,000 to 25,000 psi, 25,000 to 30,000 psi, 27,500 to 30,000 psi, 27,500 to 32,000 psi, 30,000 to 32,000 psi, 30,000 to 35,000 psi, 35,000 to 40,000 psi, 40,000 to 45,000 psi, or 45,000 to 50,000 psi. In some embodiments disclosed herein, the pressure of the homogenization or microfluidization is about 10,000 psi, 20,000 psi, or 30,000 psi. In one embodiment, the pressure is between 10,000 and 30,000 psi.
- The homogenization or microfluidization may be a single pass or run, or comprise multiple passes or runs. In one embodiment, the pressure of one or more of the multiple passes or runs may be that same for each pass. For example, the pressure of the first pass can be about 10,000 psi and the pressure of the second pass can be about 10,000 psi; the pressure of the first pass can be about 20,000 psi and the pressure of the second pass can be about 20,000 psi; or the pressure of the first pass can be about 30,000 psi and the pressure of the second pass can be about 30,000 psi; or any of the microfluidization pressures disclosed herein. Multiple passes can be two or more passes, such as three passes, four passes, five passes, six passes, seven passes, eight passes, and so on. In another embodiment, the pressure of one or more of the multiple passes or runs may be different. For example, the pressure of the first pass can be about 10,000 psi and the pressure of the second pass can be about 20,000 psi; the pressure of the first pass can be about 20,000 psi and the pressure of the second pass can be about 30,000 psi; the pressure of the first pass can be about 30,000 psi and the pressure of the second pass can be about 20,000 psi; or the pressure of the first pass can be about 10,000 psi and the pressure of the second pass can be about 30,000 psi, or any combination of the microfluidization pressures disclosed herein. Multiple passes can be two or more passes, such as three passes, four passes, five passes, six passes, seven passes, eight passes, and so on.
- The buffer conditions of the solution of extracellular vesicles may also be altered to optimize homogenization and payload molecule loading. In one embodiment, the buffer may be a phosphate buffered saline (PBS) with sucrose. PBS is a well-known buffer to those skilled in the art. In one embodiment, the PBS buffer also comprises 0.5-5% sucrose. The buffer can comprise about 0.5-5%, 0.5-1%, 1-2%, 2-3%, 3-4%, 4-5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5% sucrose. Additional buffer modifications may also be used, such as shear protectants, viscosity modifiers, and/or solutes that affect vesicle structural properties. Excipients may also be added to improve the efficiency of the homogenization or microfluidization such as membrane softening materials and molecular crowding agents. Other modifications to the buffer may include specific pH ranges and/or concentrations of salts, organic solvents, small molecules, detergents, zwitterions, amino acids, polymers, and/or any combination of the above including multiple concentrations.
- The pH of the buffer may also be altered. The pH can be between 3-13, 3-5, 5-10, 7-8, 8-10, 10-13. The pH can be about 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 6.8, 7, 7.2, 7.4, 7.5, 7.6, 7.8, 8, 8.2, 8.4, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, or 13. In one embodiment, the pH is between 3 and 13. In one embodiment, the pH is between 7 and 8. In a further embodiment, the pH is 7.4.
- The temperature of the homogenization or microfluidization may be changed for optimization of loading the payload molecules. The temperature can be between about 15-90° C., 15-20° C., 20-25° C., 25-30° C., 30-35° C., 35-40° C., 45-50° C., 50-55° C., 55-60° C., 60-65° C., 65-70° C., 70-75° C., 75-80° C., 80-85° C., or 85-90° C. The temperature can be about 15° C., 20° C., 25° C., 27° C., 30° C., 32° C., 35° C., 40° C., 45° C., 50° C., 55° C., 60° C., 65° C., 70° C., 75° C., 80° C., 85° C., or 90° C. In one embodiment, the temperature may be room temperature. In another embodiment, the temperature is 15° C. to 80° C. In another embodiment, the temperature is 70-80° C.
- The volume of the solution comprising extracellular vesicles to be homogenized or microfluidized may also be altered. The volume can be from about 1 ml to about 5000 ml, or more. The volume can be at least about 1-10 ml, 10-50 ml, 50-100 ml, 100-150 ml, 150-200 ml, 200-250 ml, 250-300 ml, 300-350 ml, 350-400 ml, 400-450 ml, 450-500 ml, 500-550 ml, 550-600 ml, 600-650 ml, 650-700 ml, 750-800 ml, 800-850 ml, 850-900 ml, 950-1000 ml, 1000-1500 ml, 1500-2000 ml, 2000-2500 ml, 2500-3000 ml, 3000-3500 ml, 3500-4000 ml, 4000-4500 ml, 45000-5000 ml, or more. The volume can be at least about 1 ml, 10 ml, 20 ml, 30 ml, 40 ml, 50 ml, 60 ml, 70 ml, 80 ml, 90 ml, 100 ml, 150 ml, 200 ml, 250 ml, 300 ml, 350 ml, 400 ml, 450 ml, 500 ml, 550 ml, 600 ml, 650 ml, 700 ml, 750 ml, 800 ml, 850 ml, 900 ml, 950 ml, 1000 ml, 1500 ml, 2000 ml, 2500 ml, 3000 ml, 3500 ml, 4000 ml, 4500, ml or 5000 ml. In one embodiment, the volume is less than a liter. In another embodiment, the volume is more than a liter. In another embodiment, the volume of the solution may be at least 1 ml.
- The extracellular vesicles may also be treated with additional technologies before or after homogenization. In one embodiment, the vesicles are pre-treated before homogenization. In one embodiment, the vesicles are post-treated after homogenization. The treatment may include a chemical treatment, such as acidic or basic buffers, or other chemical treatments not described herein.
- The extracellular vesicle may be modified with a single payload molecule or with a plurality of payload molecules. A detailed description of such payload molecules is disclosed below. In one embodiment, the extracellular vesicles may be modified with a plurality of payload molecules. The payload molecules may be the same type or class of molecule, or a different type or class of molecule. Multiple types of payload molecules may be combined to produce vesicles modified with multivalent payload molecule cargoes. For example, the vesicle can have two types, three types, four types, five types, six types, and so on. In another embodiment, the payload molecules may be predominantly on the surface of the modified vesicle. In another embodiment, the payload molecules may be predominantly inside the modified vesicle. The extracellular vesicles to be modified may be homogenized first and the payload molecules added to the homogenized vesicle solution. In a further embodiment, the extracellular vesicles and the payload molecules are mixed together and the mixture is homogenized.
- The homogenization may be applied in a batch mode, a semi-batch mode, or a continuous process. Either batch or continuous process may rely on feedback to control the homogenization or microfluidization parameters and/or terminate the process.
- Extracellular Vesicles
- Extracellular vesicles can be extracted from the supernatant of parent cells and demonstrate membrane and internal protein, lipid, and nucleic acid compositions that enable their efficient delivery to and interaction with recipient cells. Extracellular vesicles can be derived from parent cells that may include, but are not limited to, reticulocytes, erythrocytes, megakaryocytes, platelets, neutrophils, tumor cells, connective tissue cells, neural cells and stem cells. Suitable sources of extracellular vesicles include but are not limited to, cells isolated from subjects from patient-derived hematopoietic or erythroid progenitor cells, immortalized cell lines, or cells derived from induced pluripotent stem cells, optionally cultured and differentiated. Cell culture protocols can vary according to compositions of nutrients, growth factors, starting cell lines, culture period, and morphological traits by which the resulting cells are characterized. In some embodiments, the samples comprising extracellular vesicles are derived from a plurality of donor cell types (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 50, 100, 500, 1000, 5000, or 10000 donor cell types) and are combined or pooled. Pooling may occur by mixing cell populations prior to extracellular vesicles extraction or by mixing isolated extracellular vesicles compositions from subsets of donor cell types. Parent cells may be irradiated or otherwise treated to affect the production rate and/or composition pattern of secreted extracellular vesicles prior to isolation.
- In some embodiments, the extracellular vesicle comprises a membrane that forms a particle that has a diameter of between about 10-100 nm, 50-150 nm, 30-100 nm, 40-100 nm, 20-150 nm, 20-200 nm, 80-125 nm, 40-250 nm, 20-500 nm, or between about 10-1000 nm. The vesicle particle can have diameter of about 10, 150, 100, 120, 125, 130, 135, 140, 145, 150, 155, 160, 175, 200, 225, 250, 275, 300, 325, 250, 275, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, or 1000 nm. In some embodiments, the membrane comprises lipids and fatty acids. In some embodiments, the membrane comprises one or more of phospholipids, glycolipids, fatty acids, sphingolipids, phosphoglycerides, sterols, cholesterols, and phosphatidylserine. In addition, the membrane may comprise one or more polypeptides and one or more polysaccharides, such as glycans.
- In some embodiments, the extracellular vesicle is generated by a producer cell (or parental cell), such as, e.g., a mammalian cell. In some embodiments, the membrane of the extracellular vesicle comprises one or more molecules derived from the producer cell. The extracellular vesicle may be generated in a cell culture system and isolated, e.g. by separating the extracellular vesicle from the producer cell. Separation may be achieved by sedimentation. For example, the extracellular vesicle can have a specific density between 0.5-2.0, 0.5-0.75, 0.5-1, 0.75-1.5, 0.75-2, 1-2, 1.5-2, and 0.9-1.1 kg/m3. The extracellular vesicle can have a specific density about 0.5, 0.75, 1, 1.25, 1.5, 1.75, or 2 kg/m3.
- In some embodiments, the extracellular vesicle delivers the payload molecule to a target. The payload molecule is a therapeutic agent that acts on a target (e.g. a target cell) that is contacted with the extracellular vesicle. Contacting may occur, e.g. in vitro or in a subject. Payloads that may be introduced into an extracellular vesicle and/or a producer cell include therapeutic agents such as, nucleotides (e.g. nucleotides comprising a detectable moiety or a toxin or that disrupt transcription), nucleic acids (e.g. DNA or mRNA molecules that encode a polypepetide such as an enzyme, or RNA molecules that have regulatory function such as miRNA, dsDNA, lncRNA, siRNA), amino acids (e.g. amino acids comprising a detectable moiety or a toxin or that disrupt translation), polypeptides (e.g. enzymes), lipids, carbohydrates, and small molecules (e.g. small molecule drugs and toxins). The payload may comprise nucleotides, e.g. nucleotides that are labeled with a detectable or cytotoxic moiety (e.g. a radiolabel).
- In some embodiments, the extracellular vesicle comprises nucleotides and/or polynucleotides (e.g. nucleic acids). For example, the extracellular vesicle may comprise RNA, DNA, mRNA, miRNA, dsDNA, lncRNA, siRNA, or singular nucleotides. In some embodiments, the nucleotides and polynucleotides are synthetic. For example, an exogenous nucleic acid may be introduced into the extracellular vesicle and/or the producer cell. In some embodiments, the nucleic acid is DNA that can be transcribed into an RNA (e.g. an siRNA or mRNA) and in the case of an mRNA may be translated into a desired polypeptide. In some embodiments, the nucleic acid is an RNA (e.g. an siRNA or mRNA) and in the case of an mRNA may be translated into a desired polypeptide.
- In some embodiments, the extracellular vesicle comprises a nucleic acid, such as a RNA or DNA. The nucleic acid is delivered to a target cell as a payload. The target cell may transcribe a DNA payload into an RNA such as a siRNA. In case an mRNA is transcribed by the target cell form the DNA payload, the cell may translate the mRNA into a polypeptide (e.g. therapeutic polypeptide). The target cell may also translate a delivered mRNA payload into a polypeptide.
- In some embodiments, the producer cell comprises a nucleic acid that may be transcribed (e.g. a DNA may be transcribed into a siRNA or mRNA) and in case a mRNA is made the mRNA may be translated by the producer cell into a polypeptide. The producer cell may also be modified with a non-translatable RNA (e.g. siRNA or miRNA). In case a mRNA is transferred the producer cell may translate the mRNA into a polypeptide. Extracellular vesicles derived from the producer cell may then carry the non-translatable RNA, the transcribed RNA or the translated polypeptide as a payload. In certain embodiments, the nucleic acid payload is a modified nucleic acid. In some embodiments, said modified nucleic acid is an siRNA or miRNA that is modified to additionally comprise one or more cholesterol molecules. The cholesterol modifications on the nucleic acid payloads may increase the association between the nucleic acid and the inner and/or outer membrane of the extracellular vesicles, therefore increasing the maximal loading capacity of the extracellular vesicles. In some embodiments, said cholesterol is chemically conjugated to the 5′ end of the sense, or passenger strand of the siRNA or miRNA. In some embodiments, said cholesterol is chemically conjugated to the 3′ end of the sense, or passenger strand of the siRNA or miRNA. In some embodiments, said cholesterol is chemically conjugated to the 5′ end of the antisense, or guide strand of the siRNA or miRNA. In some embodiments, said cholesterol is chemically conjugated to the 3′ end of the antisense, or guide strand of the siRNA or miRNA.
- The extracellular vesicles may interact with the target cell via membrane fusion and deliver payloads (e.g., therapeutic agents) in an extracellular vesicle composition to the surface or cytoplasm of a target cell. In some embodiments, membrane fusion occurs between the extracellular vesicles and the plasma membrane of a target cell. In other embodiments, membrane fusion occurs between the extracellular vesicles and an endosomal membrane of a target cell.
- Methods of Isolating Extracellular Vesicles
- The extracellular vesicles may be isolated from the producer cells. It is contemplated that all known manners of isolation of extracellular vesicles are deemed suitable for use herein. For example, physical properties of extracellular vesicles may be employed to separate them from a medium or other source material, including separation on the basis of electrical charge (e.g., electrophoretic separation), size (e.g., filtration, molecular sieving, etc), density (e.g., regular or gradient centrifugation), Svedberg constant (e.g., sedimentation with or without external force, etc). Alternatively, or additionally, isolation may be based on one or more biological properties, and include methods that may employ surface markers (e.g., for precipitation, reversible binding to solid phase, FACS separation, specific ligand binding, non-specific ligand binding, etc.). In yet further contemplated methods, the extracellular vesicles may also be fused using chemical and/or physical methods, including PEG-induced fusion and/or ultrasonic fusion.
- Isolation (and enrichment) can be done in a general and non-selective manner (typically including serial centrifugation). Alternatively, isolation and enrichment can be done in a more specific and selective manner (e.g., using producer cell-specific surface markers). For example, specific surface markers may be used in immunoprecipitation, FACS sorting, affinity purification, bead-bound ligands for magnetic separation etc.
- In certain preferred embodiments, isolation can be done by affinity purification. For example, the extracellular vesicle can be purified by binding a population comprising extracellular vesicles to a resin, said resin comprising a plurality of ligands that have specific affinity for one or more target proteins on the surface of the extracellular vesicle. The one or more target protein may be a tetraspanin (e.g., CD63, CD81 and/or CD9), an EWI protein/immunoglobulin superfamily member (e.g., PTGFRN, IGSF8 and/or IGSF3), an integrin (e.g., ITGB1 and/or ITGA4), an ATP transporter protein (e.g., ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3 and/or ATP2B4), SLC3A2, BSG, or CD98hc. The target protein may additionally be the immunomodulating component that is displayed on the surface of the exosomes.
- In some embodiments, size exclusion chromatography can be utilized to isolate the extracellular vesicles. Size exclusion chromatography techniques are known in the art. Exemplary, non-limiting techniques are provided herein. In some embodiments, a void volume fraction is isolated and comprises the extracellular vesicles of interest. Further, in some embodiments, the extracellular vesicles can be further isolated after chromatographic separation by centrifugation techniques (of one or more chromatography fractions), as is generally known in the art. In some embodiments, for example, density gradient centrifugation can be utilized to further isolate the extracellular vesicles. Still further, in some embodiments, it can be desirable to further separate the producer cell-derived extracellular vesicles from extracellular vesicles of other origin. For example, the producer cell-derived extracellular vesicles can be separated from non-producer cell-derived extracellular vesicles by immunosorbent capture using an antigen antibody specific for the producer cell.
- In some embodiments, the isolation of extracellular vesicles may involve combinations of methods that include, but are not limited to, differential centrifugation, size-based membrane filtration, concentration and/or rate zonal centrifugation.
- Particle size may be quantified after the extracellular vesicles are isolated using any appropriate technique, including dynamic light scattering or nanoparticle tracking analysis. The diameter of the extracellular vesicles in a population can also be described using particle size distribution (D values). D values reflect the mass of the extracellular vesicles in a population as a percentage when the particles are arranged on an ascending mass basis. For instance, the D10 value is the diameter at which 10% of the extracellular vesicles population mass is comprised of extracellular vesicles less than the indicated diameter value. In such a case, the population of extracellular vesicles is comprised mainly of vesicles larger than the indicated diameter value. The D50 value is the diameter at which 50% of the extracellular vesicles population mass is comprised of vesicles less than the indicated diameter value and 50% of the extracellular vesicles population mass is comprised of vesicles larger than the indicated value. In such a case, the population of extracellular vesicles is comprised equally of vesicles larger than the indicated diameter value and smaller than the indicated diameter. The D90 value is the diameter at which 90% of the extracellular vesicles population mass is comprised of extracellular vesicles less than the indicated diameter value. In this case, the population of extracellular vesicles is comprised mainly of vesicles smaller than the indicated diameter value.
- Payload Molecules
- Extracellular vesicles may comprise payloads such as peptides, proteins, DNA, RNA, siRNA, and other macromolecules and small therapeutic molecules. In some embodiments, the payload is transferred to a producer cell by applying controlled injury to the cell for a predetermined amount of time in order to cause perturbations in the cell membrane such that the payload can be delivered to the inside of the cell (e.g., cytoplasm). In some embodiments the payload is transferred to a extracellular vesicles isolated from a producer cell by applying controlled injury to the extracellular vesicles for a predetermined amount of time in order to cause perturbations in the complex membrane such that the payload can be delivered to the inside of the extracellular vesicles. In some embodiments the payload of the extracellular vesicles may be loaded within the membrane or interior portion of the extracellular vesicles.
- The payload may be a therapeutic agent selected from a variety of known small molecule pharmaceuticals. Alternatively, the payload may be a therapeutic agent selected from a variety of macromolecules, such as, e.g., an inactivating peptide nucleic acid (PNA), an RNA or DNA oligonucleotide aptamer, an interfering RNA (iRNA), a peptide, or a protein.
- In some embodiments, the payload that may be delivered to a target by a extracellular vesicles includes, but is not limited to, RNA, DNA, siRNA, mRNA, lncRNA, iRNA, polypeptides, enzymes, cyotkines, antibodies, antibody fragments, small molecules, chemotherapeutics, metals, viral particles, imaging agents, and plasmids.
- In some embodiments the payload of the extracellular vesicles is a nucleic acid molecule, e.g. mRNA or DNA, and the extracellular vesicles targets the payload to the cytoplasm of the recipient or target cell, such that the nucleic acid molecule can be translated (if mRNA) or transcribed and translated (if DNA) and thus produce the polypeptide encoded by the payload nucleic acid molecule within the target cell. In one embodiment the polypeptide encoded by the payload nucleic acid molecule is secreted by the target cell, thus modulating the systemic concentration or amount of the polypeptide encoded by the payload nucleic acid molecule in the subject. In one embodiment the polypeptide encoded by the payload nucleic acid molecule is not secreted by the target cell, thus modulating the intracellular concentration or amount of the polypeptide encoded by the payload nucleic acid molecule in the subject. In one embodiment the polypeptide encoded by the payload nucleic acid molecule is toxic to the target cell or to other cell or tissue in the subject, e.g. toxic to a cancer cell. In one embodiment, the polypeptide encoded by the payload nucleic acid molecule is not toxic to the target cell or other cell or tissue in the subject, e.g. is therapeutically beneficial or corrects a disease phenotype.
- In some embodiments the payload of the extracellular vesicles may be a membrane protein delivered to the plasma membrane or endosomal membrane of the recipient cell.
- Extracellular vesicles may comprise two or more payloads, including mixtures, fusions, combinations and conjugates, of atoms, molecules, etc. as disclosed herein, for example including but not limited to, a nucleic acid combined with a polypeptide; two or more polypeptides conjugated to each other; a protein conjugated to a biologically active molecule (which may be a small molecule such as a prodrug); and the like.
- Suitable payloads include, without limitation, pharmacologically active drugs and genetically active molecules, including antineoplastic agents, anti-inflammatory agents, hormones or hormone antagonists, ion channel modifiers, and neuroactive agents. Examples of suitable payloads of therapeutic agents include those described in, “The Pharmacological Basis of Therapeutics,” Goodman and Gilman, McGraw-Hill, New York, N.Y., (1996), Ninth edition, under the sections: Drugs Acting at Synaptic and Neuroeffector Junctional Sites; Drugs Acting on the Central Nervous System; Autacoids: Drug Therapy of Inflammation; Water, Salts and Ions; Drugs Affecting Renal Function and Electrolyte Metabolism; Cardiovascular Drugs; Drugs Affecting Gastrointestinal Function; Drugs Affecting Uterine Motility; Chemotherapy of Parasitic Infections; Chemotherapy of Microbial Diseases; Chemotherapy of Neoplastic Diseases; Drugs Used for Immunosuppression; Drugs Acting on Blood-Forming organs; Hormones and Hormone Antagonists; Vitamins, Dermatology; and Toxicology, all incorporated herein by reference. Suitable payloads further include toxins, and biological and chemical warfare agents, for example see Somani, S. M. (ed.), Chemical Warfare Agents, Academic Press, New York (1992)).
- In some embodiments, the payload is a therapeutic agent, such as a small molecule drug or a large molecule biologic. Large molecule biologics include, but are not limited to, a protein, polypeptide, or peptide, including, but not limited to, a structural protein, an enzyme, a cytokine (such as an interferon and/or an interleukin), a polyclonal or monoclonal antibody, or an effective part thereof, such as an Fv fragment, which antibody or part thereof, may be natural, synthetic or humanized, a peptide hormone, a receptor, or a signaling molecule. In certain embodiments, the protein payload is a Cas9 protein, a TALEN, a zinc finger nuclease, or other component of a genome-editing complex.
- Large molecule biologics are immunoglobulins, antibodies, Fv fragments, etc., that are capable of binding to antigens in an intracellular environment. These types of molecules are known as “intrabodies” or “intracellular antibodies.” An “intracellular antibody” or an “intrabody” includes an antibody that is capable of binding to its target or cognate antigen within the environment of a cell, or in an environment that mimics an environment within the cell. Selection methods for directly identifying such “intrabodies” include the use of an in vivo two-hybrid system for selecting antibodies with the ability to bind to antigens inside mammalian cells. Such methods are described in PCT/GB00/00876, incorporated herein by reference. Techniques for producing intracellular antibodies, such as anti-β-galactosidase scFvs, have also been described in Martineau et al., J Mol Biol 280:117-127 (1998) and Visintin et al., Proc. Natl. Acad. Sci. USA 96:11723-1728 (1999).
- Large molecule biologics include but is not limited to, at least one of a protein, a polypeptide, a peptide, a nucleic acid, a virus, a virus-like particle, an amino acid, an amino acid analogue, a modified amino acid, a modified amino acid analogue, a steroid, a proteoglycan, a lipid and a carbohydrate or a combination thereof (e.g., chromosomal material comprising both protein and DNA components or a pair or set of effectors, wherein one or more convert another to active form, for example catalytically).
- A large molecule biologic may include a nucleic acid, including, but not limited to, an oligonucleotide or modified oligonucleotide, an antisense oligonucleotide or modified antisense oligonucleotide, an aptamer, a cDNA, genomic DNA, an artificial or natural chromosome (e.g., a yeast artificial chromosome) or a part thereof, RNA, including an siRNA, a shRNA, mRNA, tRNA, rRNA or a ribozyme, or a peptide nucleic acid (PNA); a virus or virus-like particles; a nucleotide or ribonucleotide or synthetic analogue thereof, which may be modified or unmodified. Said modification may be a lipophilic modification including addition of a cholesterol molecule, myristoylation, PEGylation, and/or palmitoylation.
- The large molecule biologic can also be an amino acid or analogue thereof, which may be modified or unmodified or a non-peptide (e.g., steroid) hormone; a proteoglycan; a lipid; or a carbohydrate. If the large molecule biologic is a polypeptide, it can be loaded directly into a producer cell according to the methods described herein. Alternatively, an exogenous nucleic acid encoding a polypeptide, which sequence is operatively linked to transcriptional and translational regulatory elements active in a producer cell at a target site, may be loaded.
- Small molecules, including inorganic and organic chemicals, may also be used as payloads of the extracellular vesicles described herein.
- In some embodiments, the small molecule is a pharmaceutically active agent. Useful classes of pharmaceutically active agents include, but are not limited to, antibiotics, anti-inflammatory drugs, angiogenic or vasoactive agents, growth factors and chemotherapeutic (anti-neoplastic) agents (e.g., tumour suppressers).
- In some embodiments, the payload molecule comprises an agonist or activator of stimulator of interferon genes (STING). The STING agonist may be a cyclic dinucleotide (CDN). Exemplary CDNs, including but not limited to cyclic diguanylate monophosphate (c-di-GMP), are described in Nature 2011, DOI: 10.1038/nature10429 and Nat. Chem. Biol. 2014, DOI: 10.1038/nchembio.1661. The STING agonist may be a small molecule agonist.
- A payload may be expressed by a target cell from a transgene or mRNA introduced into a extracellular vesicles by electroporation, chemical or polymeric transfection, viral transduction, mechanical membrane disruption, or other method when the target cell is contacted with the extracellular vesicles.
- In some instances, the exogenous nucleic acid is an RNA molecule, or a DNA molecule that encodes for an RNA molecule, that silences or represses the expression of a target gene. For example, the molecule can be a small interfering RNA (siRNA), an antisense RNA molecule, or a short hairpin RNA (shRNA) molecule.
- Pharmaceutical Compositions and Dosage Forms
- Provided herein are pharmaceutical compositions comprising extracellular vesicles that are suitable for administration to a subject. The pharmaceutical compositions generally comprise a plurality of extracellular vesicles and a pharmaceutically-acceptable excipient or carrier in a form suitable for administration to a subject. Pharmaceutically-acceptable excipients or carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions comprising a plurality of extracellular vesicles. (See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 18th ed. (1990)). The pharmaceutical compositions are generally formulated sterile and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.
- In some embodiments, the pharmaceutical composition comprises one or more therapeutic agents and the extracellular vesicles described herein. In some embodiments, the extracellular vesicles are co-administered with of one or more separate therapeutic agents, wherein co-administration includes administration of the separate therapeutic agent before, after or concurrent with administration of the extracellular vesicles.
- Pharmaceutically-acceptable excipients include excipients that are generally safe (GRAS), non-toxic, and desirable, including excipients that are acceptable for veterinary use as well as for human pharmaceutical use.
- Examples of carriers or diluents include, but are not limited to, water, saline, Ringer's solutions, dextrose solution, and 5% human serum albumin. The use of such media and compounds for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or compound is incompatible with the extracellular vesicles described herein, use thereof in the compositions is contemplated. Supplementary therapeutic agents may also be incorporated into the compositions. Typically, a pharmaceutical composition is formulated to be compatible with its intended route of administration. The extracellular vesicles can be administered by parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intradermal, transdermal, rectal, intracranial, intraperitoneal, intranasal; intramuscular route or as inhalants. In one embodiment, the pharmaceutical composition comprising extracellular vesicles is administered intravenously, e.g. by injection. The extracellular vesicles can optionally be administered in combination with other therapeutic agents that are at least partly effective in treating the disease, disorder or condition for which the extracellular vesicles are intended.
- Solutions or suspensions can include the following components: a sterile diluent such as water, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and compounds for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (if water soluble) or dispersions and sterile powders. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). The composition is generally sterile and fluid to the extent that easy syringeability exists. The carrier can be a solvent or dispersion medium containing, e.g., water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, e.g., by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal compounds, e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. If desired, isotonic compounds, e.g., sugars, polyalcohols such as manitol, sorbitol, sodium chloride can be added to the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition a compound which delays absorption, e.g., aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the extracellular vesicles in an effective amount and in an appropriate solvent with one or a combination of ingredients enumerated herein, as desired. Generally, dispersions are prepared by incorporating the extracellular vesicles into a sterile vehicle that contains a basic dispersion medium and any desired other ingredients. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The extracellular vesicles can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner to permit a sustained or pulsatile release of the extracellular vesicles.
- Systemic administration of compositions comprising extracellular vesicles can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, e.g., for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the modified extracellular vesicles are formulated into ointments, salves, gels, or creams as generally known in the art.
- The invention is further illustrated by the following examples. The examples are provided for illustrative purposes only, and are not to be construed as limiting the scope or content of the invention in any way. The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., T. E. Creighton, Proteins: Structures and Molecular Properties (W.H. Freeman and Company, 1993); Green & Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th Edition (Cold Spring Harbor Laboratory Press, 2012); Colowick & Kaplan, Methods In Enzymology (Academic Press); Remington: The Science and Practice of Pharmacy, 22nd Edition (Pharmaceutical Press, 2012); Sundberg & Carey, Advanced Organic Chemistry: Parts A and B, 5th Edition (Springer, 2007).
- Exosomes were purified chromatographically from a single-use bioreactor (SUB) and formulated in PBS-Sucrose buffer (1.8 mM KH2PO4, 10 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, 5% w/v sucrose, pH 7.4). Exosomes were mixed with an siRNA targeting kras G12D at a final concentration of 2 μM siRNA and 1×1011 particles per mL in a 1×PBS, ˜1% sucrose buffer. Loading reactions were performed at a 1.0 mL scale, and processed in duplicate over a Microfluidics M110P homogenization module equipped with a F12Y (75 μm) interaction chamber (Microfludics, Westwood, Mass.). Reactions were held at 20-25° C. by using a heat-exchanger coil configured to the outlet of the interaction chamber submerged in water. Upon processing, samples were filtered using a 0.45 μm PVDF filter and stored at 4° C. Process conditions were screened in a single-pass manner at 1×104, 2×104, and 3×104 psi. Process controls were run in addition to the loading reactions. The entire experimental matrix is shown in Table 1.
-
TABLE 1 EV only siRNA only Process no Processing (ctrl) (ctrl) Sample (mixing ctrl) 10,000 psi, single pass SUB-6 UF Pool 274 uL 0 uL 274 uL 274 uL (3.7E11 p/mL) siRNA 0 uL 20 uL 20 uL 20 uL (100 μM) 1X PBS, pH 7.4 726 uL 980 uL 706 uL 706 uL Total # Samples 2 2 2 2 20,000 psi, single pass SUB-6 UF Pool 274 uL 0 uL 274 uL 274 uL siRNA 0 uL 20 uL 20 uL 20 uL 1X PBS, pH 7.4 726 uL 980 uL 706 uL 706 uL Total # Samples 2 2 2 2 30,000 psi, single pass SUB-6 UF Pool 274 uL 0 uL 274 uL 274 uL siRNA 0 uL 20 uL 20 uL 20 uL 1X PBS, pH 7.4 726 uL 980 uL 706 uL 706 uL Total # Samples 2 2 2 2 - Upon completion of processing, one set of process samples and mixing controls were assayed using nanoparticle tracking analysis (NTA) (Malvern Technologies). The results are shown in Table 2.
-
TABLE 2 Mean D10 D50 D90 Sample p/mL (nm) (nm) (nm) (nm) Mixing Control 1.11E+11 143.8 104.8 134.4 186.0 Process Sample 4.39E+10 139.9 94.3 134.7 179.0 10,000 psi Process Sample 2.57E+10 132.4 95.1 123.1 184.7 20,000 psi Process Sample 3.36E+10 134.9 93 125.9 177.5 30,000 psi - Through processing, substantial particle loss was observed as a result of sample dilution through the microfluidizer, or as a result of shear-induced homogenization. At this scale of processing, the sample volume was approximately equal to the volumetric holdup of the Microfluidics LV-1 and substantial dilution of the processed sample was expected. Additionally, relative to the mixing control, an approximately 10% reduction in the particle D10 was observed
- After processing through the microfluidizer, samples were filtered using a 0.45 μm polypropylene filter plate, and added to Panc-1 cells to assay kras knockdown using an mRNA knockdown qPCR assay. The relative kras expression of treated and control cells are shown in
FIG. 1 . Positive (non-transfected Panc-1 cells) and negative controls (Lipofectamine-transfected Panc-1 with a kras G12D siRNA) were performed in parallel. - The homogenized vesicle samples showed greater knockdown of kras expression as compared to extracellular vesicles (EV), siRNA only, or Mixing control samples. Mixing controls show similar gene expression to the negative control, and reagent only process controls (siRNA only) show normal gene expression. The 3×104 reagent controls showed knockdown when processed independently through the LV-1. When vesicles and siRNA were processed through the LV-1 Microfludizer, a pressure-dependent gene-knockdown effect is observed—with the greatest knockdown seen at a single-pass at the highest concentration of 3×104 psi. These results demonstrate that purified exosomes can be loaded with bioactive payloads and successfully deliver the payload to the cytoplasm of recipient cells.
- To determine conditions that maximized siRNA loading of exosomes, microfluidic homogenization was carried out as in Example 1 at varying concentrations of siRNA. Exosome samples were processed with kras G12D siRNAs at 0.5 μM, 2 μM, or 8 μM final concentrations. The products from each run were added to cultured Panc-1 cells at concentrations of 100 EV/cell, 500 EV/cell, 1×103 EV/cell or 1×104 EV/cell. As a positive control, Panc-1 cells were transfected with the kras G12D siRNA using Lipofectamine. As shown in
FIG. 2 , there was a concentration-dependent and dosage-dependent increase in KRAS mRNA knockdown with 8 μM siRNA and 1×104 exosomes resulting in the greatest knockdown. - Another method of loading exosomes with siRNA molecules is to use siRNA duplexes that are covalently fused to a cholesterol moiety. Cholesterol-conjugated siRNAs can associate with the exosome membrane through lipid-lipid interactions between the cholesterol molecule and the phospholipids of the exosome membrane. This loading strategy can increase effective concentration of loaded exosomes and allow for delivery of more siRNA molecules to a recipient cell.
- To determine whether microfluidic homogenization can enhance the loading of cholesterol-modified siRNAs, exosomes were loaded as in Example 1 with unmodified kras G12D siRNA or a cholesterol-tagged version of the same miRNA. For controls, these siRNAs were mixed with exosomes without microfluidic homogenization. All samples were processed at either 10,000 psi or 20,000 psi and added to Panc-1 cells at a concentration of 1×104 exosomes per cell. As shown in
FIG. 3 , at 30,000 psi both the unmodified and cholesterol-tagged siRNAs resulted in significant knockdown of the kras G12D transcript, while none of the mixing controls altered the levels of the transcript. Interestingly, the cholesterol-tagged siRNA could efficiently knock down the transcript at 20,000 psi, while there was very modest knockdown of the transcript at 20,000 psi with the unmodified siRNA. These results demonstrate that microfluidic homogenization can be used for loading lipid-modified siRNAs, and that efficient loading of the siRNAs can be accomplished at relatively low processing pressure. - To understand the effects of the forces exerted on siRNAs during microfluidic homogenization, RNA profiles were measured for siRNAs exposed to repeated rounds of homogenization. siRNA (
FIG. 4A ) or cholesterol-tagged siRNA (FIG. 4B ) were processed at 30,000 psi once, three times or five times and analyzed by anion-exchange chromatography with detection at 254 nm. High concentration (“Mix”) and low concentration (“110 nM ctrl) control samples that were not processed were used to determine the chromatographic trace of unmodified siRNAs. As shown inFIGS. 4A and 4B , both RNA species were diluted by serial rounds of homogenization, but the shape of the chromatographic trace was not changed, indicating that the structure of the siRNA was resistant to multiple rounds of high-pressure microfluidic processing. - To determine whether the structure of exosomes was altered during repeated rounds of microfluidic homogenization, purified exosome samples were processed once, three times or five times and were analyzed by size exclusion chromatography (SEC) to determine the diameter of the exosome population. As shown in
FIGS. 5A and 5B , repeated rounds of homogenization resulted in an increase in retention time (tr), indicating the elution of smaller products (FIG. 5A ). This alteration in elution time was validated using NTA, corresponding to a change from ˜160 nm average diameter to ˜90 nm average diameter (FIG. 5B ). These results demonstrate that repeated microfluidic homogenization of exosomes results in a modest but significant decrease in diameter, perhaps due to shear-mediated fragmentation of the exosomes. - All publications, patents, patent applications and other documents cited in this application are hereby incorporated by reference in their entireties for all purposes to the same extent as if each individual publication, patent, patent application or other document were individually indicated to be incorporated by reference for all purposes.
- The present disclosure provides, inter alia, methods of producing exosomes for the delivery of payload molecules. While various specific embodiments have been illustrated and described, the above specification is not restrictive. It will be appreciated that various changes can be made without departing from the spirit and scope of the invention(s). Many variations will become apparent to those skilled in the art upon review of this specification.
Claims (36)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/190,058 US20190175506A1 (en) | 2017-11-17 | 2018-11-13 | Loading of Extracellular Vesicles through Imparting of Mechanical Shear |
US17/014,961 US20210093568A1 (en) | 2017-11-17 | 2020-09-08 | Loading of extracellular vesicles through imparting of mechanical shear |
US18/045,727 US20230301917A1 (en) | 2017-11-17 | 2022-10-11 | Loading of extracellular vesicles through imparting of mechanical shear |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762588143P | 2017-11-17 | 2017-11-17 | |
US16/190,058 US20190175506A1 (en) | 2017-11-17 | 2018-11-13 | Loading of Extracellular Vesicles through Imparting of Mechanical Shear |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/014,961 Continuation US20210093568A1 (en) | 2017-11-17 | 2020-09-08 | Loading of extracellular vesicles through imparting of mechanical shear |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190175506A1 true US20190175506A1 (en) | 2019-06-13 |
Family
ID=66734871
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/190,058 Abandoned US20190175506A1 (en) | 2017-11-17 | 2018-11-13 | Loading of Extracellular Vesicles through Imparting of Mechanical Shear |
US17/014,961 Abandoned US20210093568A1 (en) | 2017-11-17 | 2020-09-08 | Loading of extracellular vesicles through imparting of mechanical shear |
US18/045,727 Pending US20230301917A1 (en) | 2017-11-17 | 2022-10-11 | Loading of extracellular vesicles through imparting of mechanical shear |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/014,961 Abandoned US20210093568A1 (en) | 2017-11-17 | 2020-09-08 | Loading of extracellular vesicles through imparting of mechanical shear |
US18/045,727 Pending US20230301917A1 (en) | 2017-11-17 | 2022-10-11 | Loading of extracellular vesicles through imparting of mechanical shear |
Country Status (1)
Country | Link |
---|---|
US (3) | US20190175506A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021030768A1 (en) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with stat3-antisense oligonucleotides |
WO2021062317A1 (en) * | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Extracellular vesicle compositions |
WO2021128678A1 (en) * | 2019-12-27 | 2021-07-01 | 杭州迪相实业有限公司 | Method for simultaneously detecting protein, rna and exosome membrane protein in exosome |
WO2023001894A1 (en) | 2021-07-20 | 2023-01-26 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
-
2018
- 2018-11-13 US US16/190,058 patent/US20190175506A1/en not_active Abandoned
-
2020
- 2020-09-08 US US17/014,961 patent/US20210093568A1/en not_active Abandoned
-
2022
- 2022-10-11 US US18/045,727 patent/US20230301917A1/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021030768A1 (en) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with stat3-antisense oligonucleotides |
WO2021062317A1 (en) * | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Extracellular vesicle compositions |
CN114727947A (en) * | 2019-09-25 | 2022-07-08 | 科迪亚克生物科学公司 | Extracellular vesicle composition |
WO2021128678A1 (en) * | 2019-12-27 | 2021-07-01 | 杭州迪相实业有限公司 | Method for simultaneously detecting protein, rna and exosome membrane protein in exosome |
WO2023001894A1 (en) | 2021-07-20 | 2023-01-26 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
Also Published As
Publication number | Publication date |
---|---|
US20230301917A1 (en) | 2023-09-28 |
US20210093568A1 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230301917A1 (en) | Loading of extracellular vesicles through imparting of mechanical shear | |
Tateshita et al. | Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine | |
Haraszti et al. | Exosomes produced from 3D cultures of MSCs by tangential flow filtration show higher yield and improved activity | |
CN111918967A (en) | Methods and compositions for macrophage polarization | |
KR20210135494A (en) | Method for preparing lipid nanoparticles | |
US10583084B2 (en) | Liposomal formulations for delivery of nucleic acids | |
Peer | A daunting task: manipulating leukocyte function with RNA i | |
CN114502542A (en) | Nanomaterials comprising restricted lipids and uses thereof | |
Joshi et al. | Converting extracellular vesicles into nanomedicine: loading and unloading of cargo | |
US20230257738A1 (en) | Modified messenger rna comprising functional rna elements | |
Schlich et al. | Anionic liposomes for small interfering ribonucleic acid (siRNA) delivery to primary neuronal cells: Evaluation of alpha-synuclein knockdown efficacy | |
US20200345648A1 (en) | Methods and compositions for treating cancer using exosomes-associated gene editing | |
CN112533643A (en) | Use of exosomes for targeted delivery of therapeutic agents | |
Byrnes et al. | Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection | |
US20210369858A1 (en) | Use of exosomes for targeted delivery of therapeutic agents | |
Wang et al. | Extracellular Vesicles for Drug Delivery in Cancer Treatment | |
US20220251577A1 (en) | Endonuclease-resistant messenger rna and uses thereof | |
Nakamura et al. | Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles | |
US20210163928A1 (en) | Messenger rna comprising functional rna elements | |
US20210024936A1 (en) | Therapeutic targeting of oncogenes using exosomes | |
WO2023073190A9 (en) | Rna constructs and uses thereof | |
EP3781131A1 (en) | Therapeutic modulation of tumor suppressors using exosomes | |
US20230092306A1 (en) | Substance delivery carrier and composition | |
JP2024059816A (en) | Methods and compositions for treating cancer using exosome-associated gene editing | |
Schlich et al. | Anionic liposomes for siRNA delivery to primary neuronal cells: evaluation of Alpha synuclein knockdown efficacy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CODIAK BIOSCIENCES, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NOYES, AARON R.;MERCALDI, MICHAEL P.;GOLDEN, KATHRYN E.;AND OTHERS;SIGNING DATES FROM 20181129 TO 20181206;REEL/FRAME:047745/0586 |
|
AS | Assignment |
Owner name: CODIAK BIOSCIENCES, INC., MASSACHUSETTS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE 7TH INVENTOR NAME PREVIOUSLY RECORDED AT REEL: 047745 FRAME: 0586. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:NOYES, AARON R.;MERCALDI, MICHAEL P.;GOLDEN, KATHRYN E.;AND OTHERS;SIGNING DATES FROM 20181129 TO 20181206;REEL/FRAME:048044/0855 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: LONZA SALES AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CODIAK BIOSCIENCES, INC.;REEL/FRAME:064251/0794 Effective date: 20230615 |